

Abbas AK, Lichtman AH and Pober JS (1994). Tumor necrosis factor. Cellular and Molecular Immunology. Second Edition. 245-249.

Abts H, Emmerich M, Miltenyi S, Radbruch A and Tesch H (1989). CD20 positive human B lymphocytes separated with the magnetic cell sorter (MACS) can be induced to proliferation and antibody secretion in vitro. J. Immunol. Methods 125, 19-28.

Adler A, Chervenick PA, Whiteside TL, Lotzova E and Herberman RB (1988). Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71, 709-716.

Aebersold P, Carter CS, Hyatt C, Johnson S, Ottaway K, Leitman SF and Rosenberg SA (1988). A simplified automated procedure for generation of human lymphokine-activated killer cells for use in clinical trials. J. Immunol. Methods 112, 1-7.

Ahmed R and Gray D (1996). Immunological memory and protective immunity: understanding their relation. Science 272, 54-60

Aichele P, Hengartner H, Zinkernagel RM and Schulz M (1990). Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med. 171, 1815-1820.

Akbar AN, Terry L, Timms A, Beverley PCL and Janossy G (1988). Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J. Immunol. 140, 2171-2178.

Alarcon B, Ley SC, Sanchez-Madrid F, Blumberg RS, Ju ST, Fresno M and Terhorst C (1991). The CD3- γ and CD3- δ subunits of the T cell antigen receptor can be expressed within distinct functional TCR/CD3 complexes. EMBO J. 10, 903-912.

Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F and Lynch DH (1995). Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181, 71-77.

Anderson CL and Looney RJ (1986). Human leukocyte IgG Fc receptors. Immunol. Today 7, 264-266.

Anderson CL (1989). Structural and functional polymorphism of human Fc receptor for IgG. Chem. Immunol. 47, 1-20.

Anderson PM, Bach FH and Ochoa AC (1988). Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Cancer Immunol. Immunother. 27, 82-88.

Anderson PM, Crist W, Hasz D, Carroll AJ, Myers DE and Uckun FM (1992)^a. G19.4 (α CD3) X B43 (α CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4:11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 80, 2826-2834.

Anderson PM, Ochoa AC, Ramsay NKC, Hasz D and Weisdorf D (1992)^b. Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity. Blood 80, 1846-1853.

Andrieu N, Salvayre R, Jaffr  zou J-P and Levade T (1995). Low temperatures and hypertonicity do not block cytokine-induced stimulation of the sphingomyelin pathway but inhibit nuclear factor- κ B activation. J. Biol. Chem. 270, 24518-24524

Andris F, Van Mechelen M, De Mattia F, Baus E, Urbain J and Leo O (1996). Induction of T-cell unresponsiveness by anti-CD3 antibodies occurs

independently of co-stimulatory functions. Eur. J. Immunol. 26, 1187-1195.

Armitage RJ (1994). Tumor necrosis factor receptor superfamily members and their ligands. Current Opin. Immunol. 6, 407-413.

Arnaiz-Villena A, Timon M, Rodriguez-Gallego C, Pérez-Blas M, Corell A, Martin-Villa JM and Regueiro JR (1992). Human T-cell activation deficiencies. Immunol. Today 13, 259-265.

Aruffo A, Kanner SB, Sgroi D, Ledbetter JA and Stamenkovic I (1992). CD22-mediated stimulation of T cells regulates T-cell receptor/CD3-induced signalling. Proc. Natl. Acad. Sci USA 89, 10242-10246.

Asano Y and Tada T (1989). Generation of T cell repertoire. Two distinct mechanisms for generation of T suppressor cells, T helper cells, and T augmenting cells. J. Immunol. 142, 365-373.

Ashwell JD and Klausner RD (1990). Genetic and mutational analysis of the T-cell antigen receptor. Ann. Rev. Immunol. 8, 139-167.

Azuma A, Yagita H, Okumura K, Kudho S and Niitani H (1994).

Potential of long-term-cultured lymphokine-activated killer cell cytotoxicity against small-cell lung carcinoma by anti-CD3 x anti-(tumor-associated antigen) bispecific antibody. Cancer Immunol. Immunother. 38, 294-298.

Azuma M, Cayabyab M, Buck D, Phillips JH and Lanier LL (1992). CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J. Exp. Med. 175, 353-360.

Baetz K, Isaaz S and Griffiths GM (1995). Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J. Immunol. 154, 6122-6131.

Baauerle PA and Henkel T (1994). Function and activation of NF- κ B in the immune system. Annu. Rev. Immunol. 12, 141-179.

Bakker ABH, Shreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ and Figdor CG (1994). Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179, 1005-1009.

Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, Goldman CK, Brennan J, Roessler E and Waldmann TA (1994). The interleukin (IL) 2 receptor β chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 91, 4940-4944.

Bénard J, Da Silva J, De Bois M-C, Boyer P, Duvillard P, Chiric E and Riou G (1985). Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 45, 4970-4979.

Bentin J, Vaughan JH and Tsoukas CD (1988). T cell proliferation induced by anti-CD3 antibodies: requirement for a T-T cell interaction. Eur. J. Immunol. 18, 627-632.

Berg NN and Ostergaard HL (1995). Characterization of intracellular adhesion molecule-1 (ICAM-1)-augmented degranulation by cytotoxic T cells. J. Immunol. 155, 1694-1702.

Berke G (1995). The CTL's kiss of death. Cell 81, 9-12.

Berridge MJ (1993). Inositol triphosphate and calcium signalling. Nature 361, 315-325.

Berridge MJ (1995).

Inositol triphosphate and calcium signaling.
Annals New York Acad. Sci. 766: 31-43.

Beun GDM, Gorter A, Nooyen Y, van de Velde CJH and Fleuren GJ (1993).
T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model.
J. Immunol. 150, 2305-2315.

Beutler B and van Huffel C (1994).
Unraveling function in the TNF ligand and receptor families.
Science 264, 667-668.

Bino T, Frey JL and Ortaldo JR (1992).
Mechanism of target cell recognition by CD3-LGL. I. Development of a monoclonal antibody to a K562-associated target cell antigen.
Cell. Immunol. 142, 28-39.

Bolen JB (1995).
Protein tyrosine kinases in the initiation of antigen receptor signaling.
Current Opin. Immunol. 7, 306-311.

Bolhuis RLH and van de Griend RJ (1985).
Phytohemagglutinin-induced proliferation and cytolytic activity in T3⁺ but not in T3⁻ cloned T lymphocytes requires the involvement of the T3 antigen for signal transmission.
Cell. Immunol. 93, 46-57.

Bolhuis RLH, Lamers CHJ, Goey SH, Eggermont AMM, Trimbos JBMZ, Stoter G,

Lanzavecchia A, di Re E, Miotti S, Raspagliesi F, Rivoltini L and Colnaghi MI (1992).
Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: a multicenter study.
Int. J. Cancer :Suppl 7, 78-81.

Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M and Waldmann H (1993).
The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains *in vitro* immunosuppressive properties.
Eur. J. Immunol. 23, 403-411.

Bolton AE and Hunter WM (1973).
The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.
Biochem. J. 133, 529-539.

Boniface JJ and Davis MM (1995).
T-cell recognition of antigen. A process controlled by transient intermolecular interactions.
Annals New York Acad. Sci. 766, 62-69.

Bonifacino JS, Lippincott-Schwartz J, Chen C, Antusch D, Samelson LE and Klausner RD (1988).
Association and dissociation of the murine T cell receptor associated protein (TRAP).

J. Biol. Chem. 263, 8965-8971.

Bonifacino JS, Suzuki CK, Lippincott-Schwartz J, Weissman AM and Klausner RD (1989).
Pre-golgi degradation of newly synthesized T-cell antigen receptor chains: intrinsic sensitivity and the role of subunit assembly.
J. Cell Biol. 109, 73-83.

Bonnema JD, Rivlin KA, Ting AT, Schoon RA, Abraham RT and Leibson PJ (1994).
Cytokine-enhanced NK cell-mediated cytotoxicity. Positive modulatory effects of IL-2 and IL-12 on stimulus-dependent granule exocytosis.
J. Immunol. 152, 2098-2104.

Boon T, Gajewski TF and Coulie PG (1995).
From defined human tumor antigens to effective immunization.
Immunol. Today 16, 334-336.

Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG, Bernstein GM, D'Andrea AD, Ritz J and Nadler LM (1994)^a.
Prevention of T cell anergy by signaling through the γ_c chain of the IL-2 receptor.
Science 266, 1039-1042.

Boussiotis VA, Gribben JG, Freeman GJ and Nadler LM (1994)^b.
Blockade of the CD28 costimulatory pathway: a means to induce tolerance.
Current Opin. Immunol. 6, 797-807.

Braakman E, Goedegebuure PS, Vreugdenhil RJ, Segal DM, Shaw S and Bolhuis RL (1990).

ICAM⁻ melanoma cells are relatively resistant to CD3-mediated T-cell lysis.

Int. J. Cancer 46, 475-80.

Bradford M.M. (1976).

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Anal. Biochem. 72, 248-254.

Bradley LM, Croft M and Swain SL (1993).

T-cell memory: new perspectives.

Immunol. Today 14, 197-199.

Brasseur F, Marchand M, Vanwijck R, Hérin M, Lethé B, Chomez P and Boon T (1992).

Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors.

Int. J. Cancer 52, 839-841.

Breitmeyer JB, Oppenheim SO, Daley JF, Levine HB and Schlossman SF (1987).

Growth inhibition of human T cells by antibodies recognizing the T cell antigen receptor complex.

J. Immunol. 138, 726-731.

Brenner MB, McLean J, Dialynas DP, Strominger JL, Smith JA, Owen FL, Seidman JG, Ip S, Rosen F and Krangel MS (1986)

Identification of a putative second T-cell receptor. Nature 322, 145-149.

Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P and Boon T (1993).

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

J. Exp. Med. 178, 489-495.

Brottier P, Boumsell L, Gelin C and Bernard A (1985).

T cell activation via CD2 [T, gp50] molecules: accessory cells are required to trigger T cell activation via CD2-D66 plus CD2-9.6/T11(1) epitopes.

J. Immunol. 135, 1624-1631.

Browning JL, Ngam-ek A, Lawton P, DeMarinis J, Tizard R, Chow EP., Hession C, O'Brine-Greco B, Foley SF and Ware CF. (1993).

Lymphotoxin β a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface.

Cell 72, 847-856.

Brunda MJ, Tarnowski D and Davatelis V (1986).

Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.

Int. J. Cancer 37, 787-793.

Brunda MJ, Luistro L, Warriar RR, Wright RB, Hubbard BR, Murphy M, Wolf SF and Gately MK (1993).

Antitumor and antimetastatic activity of interleukin 12 against murine tumors.

J. Exp. Med. 178, 1223-1230.

Brunner KT, Manuel J, Cerottini JC and Chapuis B (1968).

Quantitative assay of the lytic action of immune lymphoid cells on ⁵¹Cr-labeled allogeneic target cells *in vitro*: inhibition by isoantibody and by drugs.

Immunology 14: 181-196.

Bulkley GB, Cohen MH, Banks PM, Char DH and Ketcham AS (1975).

Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile.

Cancer 36, 485-494.

Campbell IG, Jones TA, Foulkes WD and Trowsdale J (1991).

Folate-binding protein is a marker for ovarian cancer.

Cancer Res. 51, 5329-5338.

Campbell MJ, Carrol W, Kon S, Thielemans K, Rothbard JB, Levy S and Levy R (1987).

Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.

J. Immunol. 139, 2825-2833.

Canevari S, Mezzanzanica D, Ménard S, Ferrini S, Moretta L and Colnaghi MI (1992). Possible targets on carcinoma for biMAb retargeting of lymphocyte or drug cytotoxicity. Int. J. Cancer: Suppl 7, 42-44.

Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di RE EM, Eggermont AMM, Goeij SH, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, Ravagnani F, Scarfone G, Trimbos JB, Warnaar SO and Bolhuis RLH (1995). Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 87, 1463-1469.

Cantrell D (1994). G proteins in lymphocyte signalling. Current Opin. Immunol. 6, 380-384.

Carson WE, Giri JG, Lidmann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann, Grabstein K and Caligiuri (1994). Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395-1403.

Cepko CL, Roberts BE and Mulligan RC (1984). Construction and applications of a highly

transmissible murine retrovirus shuttle vector. Cell 37, 1053-1062.

Cerdan C, Lipcey C, Lopez M, Nunes J, Pierres A, Mawas C and Olive D (1989). Monoclonal antibodies against LFA-1 or its ligand ICAM-1 accelerate CD2 (T11.1 + T11.2)-mediated T cell proliferation. Cell. Immunol. 123, 344-353.

Cerdan C, Martin Y, Courcoul M, Mawas C, Birg F and Olive D (1995). CD28 costimulation Up-regulates long-term IL-2R β expression in human T cells through combined transcriptional and post-transcriptional regulation. J. Immunol. 154, 1007-1013.

Cesano A, Visonneau S, Clark SC and Santoli D (1993). Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J. Immunol. 151, 2943-2957.

Ceuppens JL, Meurs L, Baroja ML and Van Wauwe JP (1986). Effect of T3 modulation on pokeweed mitogen-induced T cell activation: evidence for an alternative pathway of T cell activation. J. Immunol. 136, 3346-3350.

Ceuppens JL and Van Vaeck F (1987). Direct demonstration of binding of anti-Leu 4 antibody to the 40 kDa Fc

receptor on monocytes as a prerequisite for anti-Leu 4-induced T cell mitogenesis. J. Immunol. 139, 4067-4071.

Ceuppens JL and Van Vaeck F (1989). Human T cell activation induced by a monoclonal mouse IgG3 anti-CD3 antibody (RIV9) requires binding of the Fc part of the antibody to the monocytic 72-kDa high-affinity Fc receptor (FcRI). Cell. Immunol. 118, 136-146.

Chan AC, Iwashima M, Turck CW and Weiss A (1992). ZAP-70: A 70 kd protein-tyrosine kinase that associates with the TCR ζ chain. Cell 71, 649-662.

Chatenoud L, Baudrihay MF, Kreis H, Goldstein G, Schindler J and Bach J-F (1982). Human *in vivo* antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur. J. Immunol. 12, 979-982.

Chehimi J, Valiante NM, D'Andrea A, Rengaraju M, Rosado Z, Kobayashi M, Perussia B, Wolf SF, Starr SE and Trinchieri G (1993). Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur. J. Immunol. 23, 1826-1830.

Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I and Hellström KE (1994).

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.
J. Exp. Med. 179, 523-532.

Cherwinski HM, Semenuk GT and Ransom JT (1992).

Stimulation of a T helper cell class 2 clone with immobilized anti-T cell receptor antibody activates a Ca²⁺ and protein kinase C-independent lethal signaling pathway.
J. Immunol. 148, 2996-3003.

Chiapparino F, Biffi M, Luciano A, Gromo G, Leoni F (1994).

Involvement of multiple protein kinases in CD3-mediated activation of human T lymphocytes.
Cell. Immunol. 153, 39-51.

Chicz RM, Urban RG, Gorga JC, Vignalli DAA, Lane WS and Strominger JL (1993).

Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.
J. Exp. Med. 178, 27-47.

Chinn A, Cosyns M and Hayward AR (1990).

T cell proliferative response to interleukin 2: different frequency of responders among CD45R0 and CD45RA subsets.
Cell. Immunol. 131, 132-139.

Chong AS, Jiang XL, Scuderi P, Lamas M and Graf LH (1994).

ICAM-1 and LFA-3 enhance the ability of anti-CD3 mAb to stimulate interferon gamma production in interleukin-2-activated T cells.

Cancer Immunol. Immunother. 39, 127-134.

Chused TM, Wilson HA, Greenblatt D, Ishida Y, Edison LJ, Tsien RY and Finkelman FD (1987).

Flow cytometric analysis of murine splenic B lymphocyte cytosolic free calcium response to anti-IgM and anti-IgD.
Cytometry 8, 396-404.

Ciccone E, Pende D, Nanni L, Di Donato C, Viale O, Beretta A, Vitale M, Sivori S, Moretta A and Moretta L (1995).

General role of HLA class I molecules in the protection of target cells from lysis by natural killer cells: evidence that the free heavy chains of class I molecules are not sufficient to mediate the protective effect.
Int. Immunol. 7, 393-400.

Clark EA (1993).

CD22, a B cell-specific receptor, mediates adhesion and signal transduction.
J. Immunol. 150, 4715-4718.

Clement LT, Grossi CE and Gartland GL (1984). Morphologic and phenotypic features of the subpopulation of Leu-2⁺ cells that suppresses B cell differentiation.

J. Immunol. 133, 2461-2469.

Cleveland JL and Ihle JN (1995).

Contenders in FasL/TNF death signaling.
Cell 81, 479-482.

Colamonici OR,

Quinones R, Rosolen A, Trepel JB, Sausville E, Phares JC, Gress R, Poplack D, Weber J, Schechter GP and Neckers LM (1988).

The beta subunit of the interleukin-2 receptor mediates interleukin-2 induction of anti-CD3 redirected cytotoxic capability in large granular lymphocytes.
Blood 71, 825-828.

Collins SJ, Gallo RC and Gallagher RE (1977).

Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.
Nature 270, 347-349.

Collins TL, Kassner PD, Bierer BE and Burakoff SJ (1994).

Adhesion receptors in lymphocyte activation.
Current Opin. Immunol. 6, 385-393.

Constant P, Davodeau F, Peyrat M-A, Poquet Y, Puzo G, Bonneville M and Fournié JJ (1994).

Stimulation of human $\gamma\delta$ T cells by nonpeptidic mycobacterial ligands.
Science 264, 267-270.

Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora J-P, Renaud J-C and Boon T (1994).

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35-42.

Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF and Slingluff CL (1994). Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-718.

Crabtree GR (1989). Contingent genetic regulatory events in T lymphocyte activation. Science 243, 355-361.

Cronin II DC, Stack R and Fitch FW (1995). IL-4-producing CD8⁺ T cell clones can provide B cell help. J. Immunol. 154, 3118-3127.

Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG and Smith CA (1994). A lymphotoxin- β -specific receptor. Science. 264, 707-710.

Curti BD, Longo DL, Ochoa AC, Conlon KC, Smith II JW, Alvord WG, Creekmore SP, Fenton RG, Gause BL, Holmlund J, Janik JE, Ochoa J, Rice PA, Sharfman WH, Sznal M and Urba WJ (1993). Treatment of cancer patients with *ex vivo* anti-CD3-activated killer cells and interleukin-2.

J. Clin. Oncology 11, 652-660.

Dacie JV and Lewis SM (1968). Practical Hematology. IV Eds.

Darnell Jr JE, Kerr IM and Stark GR (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421.

Davis L, Vida R and Lipsky PE (1986). Regulation of human T lymphocyte mitogenesis by antibodies to CD3. J. Immunol. 137, 3758-3767.

Davis LS, Wacholtz MC and Lipsky PE (1989). The induction of T cell unresponsiveness by rapidly modulating CD3. J. Immunol. 142, 1084-1094.

Davis MM and Chien Y-H (1995). Issues concerning the nature of antigen recognition by $\alpha\beta$ and $\gamma\delta$ T-cell receptors. Immunol. Today 16: 316-318.

Debatin K-M, Goldmann CK, Bamford R, Waldmann TA and Krammer PH (1990). Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet 335, 497-500.

Deckert M, Kubar J and Bernard A (1992). CD58 and CD59 molecules exhibit potentializing effects in T

cell adhesion and activation. J. Immunol. 148, 672-677.

Deem RL, Shanahan F, Niederlehner A, and Targan SR (1988). Role of the CD45 (T-200) molecule in anti-CD3-Triggered T cell-mediated cytotoxicity. Cell. Immunol. 117, 99-110.

Degiovanni G and Schaaf-Lafontaine N (1981). FCS-activated blast T cells inhibit the in vitro response of memory CTL precursors to alloantigens by removal of factor(s) from MLC supernatant. J. Immunol. 126, 641-647.

de Haas M, Vossebeld PJM, Von dem Borne AEGK and Roos D (1995). Fc γ receptors of phagocytes. J. Lab. Clin. Med. 126, 330-341.

de Jong R, Stokkers P, Lamme E, Kool JM, Borst F, Brouwer M, Miedema F, van Lier RA (1991). Regulation of T-cell differentiation by CD2 and CD28 accessory molecules. Immunology 74, 175-82.

Delvenne P, Al-Saleh W, Gilles C, Thiry A and Boniver J (1995). Inhibition of growth of normal and human papillomavirus-transformed keratinocytes in monolayer and organotypic cultures by interferon- γ and tumor necrosis factor- α .

Am. J. Pathol. 146, 589-598.

Demanet C, Brissinck J, Van Mechelen M, Leo O and Thielemans K (1991). Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotypic X anti-CD3). J. Immunol. 147, 1091-1097.

De Maria R, Todaro M, Stassi G, Di Blasi F, Giordano M, Galluzzo A and Giordano C (1994). Defective T cell receptor/CD3 complex signaling in human type I diabetes. Eur. J. Immunol. 24, 999-1002.

Dinarello CA (1991). Interleukin-1 and interleukin-1 antagonism. Blood 77, 1627-1652.

Dohi Y, Sunada S, Aoki M, Moriguchi A, Okabayashi M, Miyata M and Matsuda H (1993). Eradication of metastatic tumour cells from lymph nodes by local administration of anti-CD3 antibody. Cancer Immunother. Immunother. 36, 357-363.

D'Orazio JA, Burke GW and Stein-Streilein J (1995). Staphylococcal enterotoxin B activates purified NK cells to secrete IFN- γ but requires T lymphocytes to augment NK cytotoxicity. J. Immunol. 154, 1014-1023.

Düchler M, Offterdinger M, Holzmüller H, Lipp J, Chu C-T, Aschauer B,

Bach FH and Hofer E (1995). NKG2-C is a receptor on human natural killer cells that recognizes structures on K562 target cells. Eur. J. Immunol. 25, 2923-2931.

Dunn PL and North RJ (1991). Early gamma interferon production by natural killer cells is important in defense against murine listeriosis. Infect. Immun. 59, 2892-2900.

Durrant LG, Buckley TJD, Denton GWL, Hardcastle JD, Sewell HF and Robins RA (1994). Enhanced cell-mediated tumor killing in patients immunized with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res. 54, 4837-4840.

Dustin ML, Rothlein R, Bhan AK, Dinarello CA and Springer TA (1986). Induction by IL-1 and interferon- γ : Tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 137, 245-254.

Eischen CM, Schilling JD, Lynch DH, Krammer PH and Leibson PJ (1996). Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J. Immunol. 156, 2693-2699.

Ellenhorn JDI, Hirsch R, Schreiber H and Bluestone JA (1988). In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science 242, 569-571.

Ellenhorn JDI, Schreiber H and Bluestone JA (1990). Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice. J. Immunol. 144, 2840-2846.

Ellis TM and Fisher RI (1989). Functional heterogeneity of Leu 19^{bright+} and Leu 19^{dim+} lymphokine-activated killer. J. Immunol. 142, 2949-2954.

Engel P, Nojima Y, Rothstein D, Zhou L-J, Wilson GL, Kehrl JH and Tedder TF (1993). The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J. Immunol. 150, 4719-4732.

Esposito G, Scarselli E, Cerino A, Mondelli MU, La Monica N and Traboni C (1995). A human antibody specific for hepatitis C virus core protein: synthesis in a bacterial system and characterization. Gene 164, 203-209.

Fady C, Gardner A, Gera JF and Lichtenstein A (1993).

Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.
Cancer Immunol Immunother 37, 329-336.

Fanger MW, Shen L, Graziano RF and Guyre PM (1989). Cytotoxicity mediated by human Fc receptors for IgG.
Immunol. Today 10, 92-99.

Fanger MW, Segal DM and Romet-Lemonne J-L (1991). Bispecific antibodies and targeted cellular cytotoxicity.
Immunol. Today 12, 51-54.

Ferrer JM, Plaza A, Kreisler M and Diaz-Espada F (1992). Differential interleukin secretion by in vitro activated human CD45RA and CD45R0 T cell subsets.
Cell. Immunol. 141, 10-20.

Ferrini S, Miescher S, Zocchi MR, Von Flidner V and Moretta A (1987). Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
J. Immunol. 138, 1297-1302.

Ferrini S, Prigione I, Mammoliti S, Colnaghi

MI, Menard S, Moretta A and Moretta L (1989). Retargeting of T-cell-receptor $\gamma\delta^+$ lymphocytes against tumor cells by bispecific monoclonal antibodies. Induction of cytolytic activity and lymphokine production.
Int. J. Cancer :Suppl. 4, 53-55.

Ferrini S, Cambiaggi A, Cantoni C, Canevari S, Mezzanzanica D, Colnaghi MI, Moretta L (1992). Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules.
Int. J. Cancer Suppl. 7, 15-18.

Ferrini S, Sforzini S, Cambiaggi A, Poggi A, Meazza R, Canevari S, Colnaghi MI and Moretta L (1994). The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes.
Int. J. Cancer 56, 846-852.

Finkel TH, McDuffie M, Kappler JW, Marrack P and Cambier JC (1987). Both immature and mature T cells mobilize Ca^{2+} in response to antigen receptor crosslinking.
Nature 330, 179-181.

Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW and O'Garra A (1991).

IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.
J. Immunol. 146, 3444-3451.

Firestein GS, Roeder WD, Laxer JA, Townsend KS, Weaver CT, Hom JT, Linton J, Torbett BE and Glasebrook AL (1989). A new murine CD4⁺ T cell subset with an unrestricted cytokine profile.
J. Immunol. 143, 518-525.

Flamand V, Sornasse T, Thielemans K, Demanet C, Leo O, Urbain J, Moser M (1993). Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma.
Adv. Exp. Med. Biol. 329, 611-616.

Flanagan WM, Corthésy B, Bram RJ and Crabtree GR (1991). Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A.
Nature 352, 803-807.

Fournel S, Morel P, Revillard JP, Lizard G and Bonnefoy-Berard N (1993). Inhibition of human T cell response to staphylococcal enterotoxin B by prior ligation of surface CD4 molecules.
Cell. Immunol. 150, 194-204.

Freedman AS, Freeman GJ, Rhyhart K and Nadler LM (1991). Selective induction of B7/BB-1 on interferon- γ

stimulated monocytes: A potential mechanism for amplification of T cell activation through the CD28 pathway.

Cell. Immunol. 137, 429-437.

Friedl F, Kimura I, Osato T and Ito Y (1970).

Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology.

Proc. Soc. Exp. Biol. Med. 135, 543-545.

Funderud S, Erikstein B, Asheim HC, Nustad K, Stokke T, Blomhoff HK, Holte H and Smeland EB (1990).

Functional properties of CD19⁺ B lymphocytes positively selected from buffy coats by immunomagnetic separation.

Eur. J. Immunol. 20, 201-206.

Furukawa T, Itoh M, Krueger NX, Streuli M and Saito H (1994).

Specific interaction of the CD45 protein-tyrosine phosphatase with tyrosine-phosphorylated CD3 ζ chain.

Proc. Natl. Acad. Sc. USA 91, 10928- 10932.

Gabriele L, Kaido T, Woodrow D, Moss J, Ferrantini M, Proletti E, Santodonato L, Rozera C, Maury C, Belardelli F and Gresser I (1995).

Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.

Am. J. Pathol. 147, 445-460.

Galandrini R, Albi N, Zarccone D, Grossi CE and Velardi A (1992).

Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.

Eur. J. Immunol. 22, 2047-2053.

Gallo-Hendrikx E, Copps J, Percy D, Croy BA and Wildeman AG (1994).

Enhancement of pancreatic tumor metastasis in transgenic immunodeficient mice.

Oncogene 9, 2983-90.

Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R and Gilboa E (1990).

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.

J. Exp. Med. 172, 1217-1224.

Gardner MJ, Jones LM, Catterall JB and Turner GA (1995).

Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis.

Cancer Letters 91, 229-234.

Gardner P (1989).

Calcium and T lymphocyte activation.

Cell 59, 15-20.

Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM and Wunderlich JR (1990).

Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in *nu/nu* mice.

Cancer Res. 50, 4227-4232.

Gee AP, Mansour VH and Weiler MB (1991).

Effects of target antigen density on the efficacy of immunomagnetic cell separation.

J. Immunol. Methods 142, 127-136.

Geisberg M and Dupont B (1992).

Cytolytic effector function is present in resting peripheral T lymphocytes.

Int. Immunol. 4, 1273-1281.

Gelfand EW, Cheung RK, Grinstein S and Mills G (1986).

Characterization of the role for calcium influx in mitogen-induced triggering of human T cells. Identification of calcium-dependent and calcium independent signals.

Eur. J. Immunol. 16, 907-912.

Gelfand EW, Cheung RK, Mills GB and Grinstein S (1988).

Uptake of extracellular Ca²⁺ and not recruitment from internal stores is essential for T lymphocyte proliferation.

Eur. J. Immunol. 18, 917-922.

Geller RL, Smyth MJ, Strobl SL, Bach FH, Ruscetti FW, Longo DL and Ochoa AC (1991).

Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits.

J. Immunol. 146, 3280-3288.

Gershenfeld HK, Hershberger RJ, Shows TB and Weissman IL (1988).

Cloning and chromosomal assignment of a human cDNA encoding a T cell- and natural killer cell-specific trypsin-like serine protease.

Proc. Natl. Acad. Sci. USA 85, 1184-1188.

Gershon RK and Kondo K (1971).

Infectious immunological tolerance.

Immunology 21, 903-14.

Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersley JH, Dosik H and Parks WP (1973).

In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.

J. Natl. Cancer Inst 51, 1417-1421.

Gill BM, Nishikata H, Chan G, Delovitch TL and Ochi A (1994).

Fas antigen and sphingomyelin-ceramide turnover-mediated signaling: Role in life and death of T lymphocytes.

Immunol. Rev. 142, 113-125.

Gilles C, Piette J, Rombouts S, Laurent C and Foidart J-M (1993).

Immortalization of human cervical keratinocytes by human papillomavirus type 33.

Int. J. Cancer 53, 872-879.

Glaichenhaus N, Shastri N, Littman DR and Turner JM (1991).

Requirement for association of p56lck with CD4 in antigen-specific signal transduction in T cells.

Cell 64, 511-520.

Goldsmith MA, Amaral MC and Greene WC (1995).

Ligand binding by the IL-2 receptor is modulated by intracellular determinants of the IL-2 receptor β -chain.

J. Immunol. 154, 2033-2040.

Grabbe S, Beissert S, Schwarz T and Granstein RD (1995).

Dendritic cells as initiators of tumor immune response: a possible strategy for tumor immunotherapy?

Immunology Today 16, 117-121

Gray D (1994).

Regulation of immunological memory.

Current Opin. Immunol. 6, 425-430.

Gray JD, Hirokawa M and Horwitz DA (1994).

The role of transforming growth factor β in the generation of suppression: An interaction between CD8⁺ T and NK cells.

J. Exp. Med. 180, 1937-1942.

Greenberg PD, Klarnet JP, Kern DE and Cheever MA (1988).

Therapy of disseminated tumors by adoptive

transfer of specifically immune T cells.

Prog. Exp. Tumor Res. 32, 104-127.

Greimers R (1990).

Cytométrie en flux: analyses multiparamétriques et tri cellulaire.

Université de Liège.

Greimers R, Rongy AM, Schaaf-Lafontaine N and Boniver J (1991).

CUBIC: a three-dimensional colored projection of Consort 30 generated trivariate flow cytometric data.

Cytometry 12, 570-578.

Greimers R. (1993).

Contribution à l'analyse multiparamétrique par cytométrie en flux de lymphome radio-induits chez la souris et de tumeurs solides humaines.

Dissertation présentée en vue de l'obtention du grade de Docteur Spécial en Sciences Biomédicales Expérimentales.

Université de Liège.

Greimers R, Trebak M, Moutschen M, Jacobs N and Boniver J (1996).

Improved four-color flow cytometry method using Fluo-3 and a triple immunofluorescence for analysis of intracellular calcium ion ([CA²⁺]_i) fluxes among mouse lymph node B- and T-lymphocyte subsets.

Cytometry 23, 205-217

Grell M, Krammer PH and Scheurich P (1994).

Segregation of APO-1/Fas antigen- and tumor necrosis factor receptor-mediated apoptosis.

Eur. J. Immunol. 24, 2563-2566.

Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA (1982). Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841.

Gryniewicz G, Poenie M and Tsien RY (1985). A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450.

Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ and Nadler LM (1994). Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 84, 3261-3282.

Guillaume T, Hamdan O, Staquet P, Sekhavat M, Chatelain B, Bosly A, Rubinstein DB, Humblet Y, Doyen C, Coiffier B, Felman P and Symann M (1993). Blunted rise in intracellular calcium in CD4+ T cells in response to mitogen following autologous bone marrow transplantation. Br. J. Haematol. 84, 131-136.

Guttinger M, Gassmann M, Amrein KE and Burn P (1992). CD45 phosphotyrosine phosphatase and p56 lck

protein tyrosine kinase: a functional complex crucial in T cell signal transduction. Int. Immunol. 4, 1325-1330.

Haagen IA, de Lau WBM, Bast BJEG, Geerars AJG, Clark MR and de Gast BC (1994). Unprimed CD4⁺ and CD8⁺ T cells can be rapidly activated by a CD3XCD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol. Immunother. 39, 391-396.

Hahn S, Gehri R and Erb P (1995). Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol. Rev. 146, 57-79.

Hamann A (1992). Mechanisms of lymphocyte traffic and cell targeting. Int. J. Cancer Suppl. 7, 19-23

Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR and Ozols RF (1984). Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44, 5286-5290.

Hammond EH, Wittwer CT, Greenwood J, Knape WA, Yowell RL, Menlove RL, Craven C, Renlund DG, Bristow MR, DeWitt CW and O'Connell JB (1990).

Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis. Transplantation 50, 776-782.

Hara T and Fu SM (1985). Human T cell activation. 1. Monocyte-independent activation and proliferation induced by anti-T3 monoclonal antibodies in the presence of tumor promoter 12-o-Tetradecanoyl Phorbol-13-acetate. J. Exp. Med. 161, 641-656.

Harding CV (1991). Pathways of antigen processing. Curr. Opin. Immunol. 3, 3-9.

Harel-Bellan A, Bertoglio J, Quillet A, Marchiol C, Wakasugi H, Mishall Z and Fradelizi D (1986). Interleukin 2 (IL-2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation. J. Immunol. 136, 2463-2469.

Haugland RP (1992-1994). Calcium indicators, chelators and ionophores. Molecular probes handbook of fluorescent probes and research chemicals. Set 20, 113

Haverstick DM, Engelhard VH and Gray LS (1991). Three intracellular signals for cytotoxic T

lymphocyte-mediated killing.
J. Immunol. 146, 3306-3313.

Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A and Stevenson FK (1994). Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines.
Blood 83, 3279-3288.

Heald R, McLoughlin M and McKeon F (1993). Human Wee 1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase.
Cell 74, 463-474.

Hellström I, Hellström KE and Yeh M-Y (1981). Lymphocyte-dependent antibodies to antigen 3.1, a cell-surface antigen expressed by a subgroup of human melanomas.
Int. J. Cancer 27, 281-285.

Heo DS, Park J-G, Hata K, Day R, Herberman RB and Whiteside TL (1990). Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity.
Cancer Res. 50: 3681-3690.

Hermann GG, Petersen KR, Steven K and Zeuthen J (1990). Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK

cytotoxicity caused by a low incidence of CD56⁺ and CD57⁺ mononuclear blood cells.
J. Clinical Immunol. 10, 311-319.

Hesketh TR, Smith GA, Moore JP, Taylor MV and Metcalfe JC (1983). Free cytoplasmic calcium concentration and the mitogenic stimulation of lymphocytes.
J. Biol. Chem. 258, 4876-4882.

Heusel JW, Wesselschmidt RL, Shersta S, Russel JH, Ley TJ (1994). Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells.
Cell 76, 977-987.

Hirsch R, Eckhaus M, Auchincloss H, Sachs DH and Bluestone JA (1988). Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in Mice.
J. Immunol. 140, 3766-3772.

Hivroz-Burgaud C, Clipstone NA and Cantrell DA (1991). Signaling requirements for the expression of the transactivating factor NF-AT in human T lymphocytes.
Eur. J. Immunol. 21, 2811-2819.

Ho S and Campana D (1991). Phenotypic changes and proliferative activity of human $\gamma\delta$ T cell receptor-bearing cells upon activation.

Clin. Exp. Immunol. 84, 376-382.

Holcombe RF, Jones KL and Stewart RM (1994). Lysosomal enzyme activities in Chediak-Higashi syndrome: evaluation of lymphoblastoid cell lines and review of the literature.
Immunodeficiency 5, 131-140.

Holliger P, Prospero T and Winter G (1993). "Diabodies": Small bivalent and bispecific antibody fragments.
Proc. Natl. Acad. Sci. USA 90, 6444-6448.

Hommel-Berrey GA, Shenoy AM and Brahmi Z (1991). Receptor modulation and early signal transduction events in cytotoxic T lymphocytes inactivated by sensitive target cells.
J. Immunol. 147, 3237-3243.

Hoskin DW, Stankova J, Anderson SK and Roder JC (1989). Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibodies.
Cancer Immunol. Immunother. 29, 226-230.

Hsieh-Ma ST, Eaton AM, Shi T and Ring DB (1992). In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1. Recognizing c-erbB-2 protooncogene product and Fc γ receptor III.
Cancer Res. 52, 6832-6839.

Hu-Li J, Shevach EM, Mizuguchi J, Ohara J, Mosmann T and Paul WE (1987).

B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J. Exp. Med. 165, 157-172.

Hurwitz R, Hozier J, Lebien T, Minowada J, Gail-Peczaska K, Kubonishi I and Kersey J (1979).

Characterization of a leukemic cell line of the pre-B phenotype. Int. J. Cancer 23, 174-180.

Ihle JN (1996).

STATs: Signal transducers and activators of transcription. Cell 84, 331-334.

Ioannides CG, Freedman RS, Platsoucas CD, Rashed S and Kim YP (1991).

Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol. 146, 1700-1707.

Isaacs A and Lindemann J (1957).

Virus interference: The interferon. Proc. R. Soc. Lond. (Biology) 147, 259-267.

Isaaz S, Baertz K, Olsen K, Podack E and Griffiths GM (1995).

Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of

the lytic granules and secretion of lytic proteins via a non-granule pathway.

Eur. J. Immunol. 25, 1071-1079.

Isakov N, Wange RL, Burgess WH, Watts JD, Aebersold R and Samelson LE (1995).

ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity.

J. Exp. Med. 181, 375-380.

Ishii N, Takeshita T, Kimura Y, Tada K, Kondo M, Nakamura M and Sugamura K (1994).

Expression of the IL-2 receptor γ chain on various populations in human peripheral blood. Int. Immunol. 6, 1273-1277.

Ishimitsu T and Torisu M (1993).

The role of eosinophils in interleukin-2/lymphokine-activated killer cell therapy. Surgery 113, 192-199.

Itoh K, Tilden AB and Balch CM (1986).

Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J. Immunol. 136, 3910-3915.

Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S-I, Sameshima M, Hase A, Seto Y and Nagata S (1991).

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243.

Jacobs N, Moutschen M, Boniver J, Greimers R and Schaaf-Lafontaine N (1991).

Cytolytic activities and T-cell receptor expression in cultures of human PBL activated with anti-CD3 mAbs.

Biol. Cell. 73, 51.

Jacobs N, Moutschen M, Boniver J, Greimers R and Schaaf-Lafontaine N (1992).

Immunoselection of cytolytic CD3⁺ and CD3⁻ effector lymphocytes using a magnetic cell sorter (MACS).

Biol. Cell. 76, 31.

Jacobs N, Moutschen MP, Boniver J, Greimers R and Schaaf-Lafontaine N (1993).

Efficient immunoselection of cytolytic effectors with a magnetic cell sorter. Res. Immunol. 144, 141-150.

Jacobs N, Greimers R, Mazzoni A, Trebak M, Schaaf-Lafontaine N, Boniver J and Moutschen MP (1996).

Further characterization of cytotoxic T cells generated by short term culture of human PBL with interleukin-2 and anti-CD3 mAb.

Cancer Immunol. Immunother. (sous presse).

Jaffe HS and Herberman RB (1988).

Rationale for recombinant human interferon- γ

adjuvant immunotherapy for cancer.

J. Nat. Cancer Inst. 80, 616-618.

Jaffers GJ, Colvin RB, Cosimi AB, Ciorgi JV, Goldstein G, Fuller TC, Kurnick JT, Lillehei C and Russel PS (1983).

The human immune response to murine OKT3 monoclonal antibody.

Transplant. Proc. 15, 646-648.

Jaffers GJ, Fuller TC, Cosimi AB, Russel PS, Winn HJ and Colvin RB (1986).

Monoclonal antibody therapy.

Transplantation 41, 573-578.

Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, Curran T and Rao A (1993).

The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun.

Nature 365, 352-355.

Jain J, Loh C and Rao A (1995).

Transcriptional regulation of the IL-2 gene.

Current Opin. Immunol. 7, 333-342.

Jenkins MK, Chen C, Jung G., Mueller DL and Schwartz RH (1990).

Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody.

J. Immunol. 144, 16-22.

Jenkins MK and Johnson JG (1993).

Molecules involved in T-cell costimulation.

Current Opin. Immunol. 5, 361-367.

Johannisson A and Festin R (1995).

Phenotype transition of CD4⁺ T cells from CD45RA to CD45RO is accompanied by cell activation and proliferation.

Cytometry 19, 343-352.

Jolliffe LK (1993).

Humanized antibodies: enhancing therapeutic utility through antibody engineering.

Int. Rev. Immunol. 10, 241-250.

Jondal M, Kullman C, Alter M-B and Ljunggren K (1986).

Monoclonal antibodies against the NK cell-FcR and the T3-complex potentiate normal lymphocyte killing.

Cell. Immunol. 100, 158-166.

Jones KL, Stewart RM, Fowler M, Fukuda M and Holcombe RF (1992).

Chediak-Higashi lymphoblastoid cell lines: granule characteristics and expression of lysosome-associated membrane proteins.

Clin. Immunol. Immunopathol. 65, 219-226.

Jones PT, Dear PH, Foote J, Neuberger MS and Winter G (1986).

Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Nature 321, 522-525.

June CH, Bluestone JA, Nadler LM and Thompson CB (1994).

The B7 and CD28 receptor families.

Immunol. Today 15, 321-331.

Jung G, Honsik CJ, Reisfeld RA and Müller-Eberhard HJ (1986).

Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates.

Proc. Natl. Acad. Sci. USA 83, 4479-4483.

Jung G, Martin DE and Müller-Eberhard HJ (1987).

Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3.

J. Immunol. 139, 639-644.

Jung G, Freimann U, Von Marschall Z, Reisfeld RA and Wilmanns W (1991).

Target cell-induced T cell activation with bi- and trisppecific antibodies fragments.

Eur. J. Immunol. 21, 2431-2435.

Kabelitz D, Pohl T and Pechhold K (1993).

Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes.

Immunol. Today 14, 338-339.

Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H and Golstein P (1994).

Fas and perforin pathways as a major mechanisms of T cell-mediated cytotoxicity. Science 265, 528-530.

Kamoun M, Zerva L, Sloan S, Zmijewski C, Monos D and Trinchieri G (1992).

Induction of HLA class II molecules on human T cells: relationship to immunoregulation and the pathogenesis of AIDS. DNA Cell Biology 11, 265-268.

Kan EA, Wang CY, Wang LC and Evans RL (1983).

Noncovalently bonded subunits of 22 and 28 kd are rapidly internalized by T cells reacted with anti-Leu-4 antibody. J. Immunol. 131, 536-539.

Kandzia J, Scholz W, Anderson MJD and Müller-Ruchholtz W (1985).

Magnetic albumin/protein A immunomicrospheres. II. Specificity, reproductibility, and resolution of the magnetic cell separation technique. Diagn. Immunol. 3, 83-88.

Kaneoka H, Perez-Rojas G, Sasasaki T, Benike CJ and Engleman EG (1983). Human T lymphocyte proliferation induced by a pan-T monoclonal antibody (anti-Leu 4): Heterogeneity of response is a function of monocytes. J. Immunol. 131, 158-162.

Kang X, Kawakami Y, El-Gamil M, Wang R, Sakaguchi K, Yanelli JR,

Appella E, Rosenberg SA and Robbins PF (1995).

Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol. 155, 1343-1348.

Kao JPY, Harootunian AT and Tsien RY (1989).

Photochemically generated cytosolic calcium pulses and their detection by fluo-3. J. Biol. Chem. 254, 8179-8184.

Kapp JA, Pierce CW, Webb DR, Devens B, Godfrey W, Fukuse S, Engleman E, Lake JP, Magnani JI, Maiti PH and Sehon A (1995).

Characterization of the epitope recognized by a mAb that reacts differentially with murine suppressor T cells. Int. Immunol. 7, 1319-1330.

Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, van der Eb A and Melief CJM (1989).

Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59, 603-614.

Kast WM, Brandt RM, Sidney J, Drijfhout J-W, Kubo RT, Grey HM, Melief CJM and Sette A (1994).

Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152, 3904-3912.

Kawahara A, Minami Y and Taniguchi T (1994).

Evidence for a critical role for the cytoplasmic region of the interleukin 2 (IL-2) receptor γ chain in IL-2, IL-4, and IL-7 signalling. Mol. Cel. Biol. 14, 5433-5440.

Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T and Rosenberg SA (1994).

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Proc. Natl. Acad. Sc. USA 91, 3515-3519.

Kawasaki A, Shinkai Y, Yagita H, Okumura K (1992).

Expression of perforin in murine natural killer cells and cytotoxic T lymphocytes in vivo. Eur. J. Immunol. 22, 1215-1219.

Kelso A (1995).

Th1 and Th2 subsets: paradigms lost? Immunol. Today 16, 374-379.

Kemeny DM, Noble A, Holmes BJ and Diaz-Sanchez D (1994).

Immune regulation: a new role for the CD8⁺ T cell. Immunol. Today 15, 107-110.

Kemshead JT, Heath L, Gibson FM, Katz F, Richmond F, Treleaven J and Ugelstad. J (1986).

Magnetic microspheres and monoclonal antibodies for the depletion of

neuroblastoma cells from bone marrow: Experiences, improvements and observations. Br. J. Cancer 54, 771-778.

Kim HT, Nelson EL, Clayberger C, Sanjanwala M, Sklar J and Krensky AM (1995). $\gamma\delta$ T cell recognition of tumor Ig peptide. J. Immunol. 154, 1614-1623.

Kimberly RP, Salmon JE and Edberg JC (1995). Receptors for immunoglobulin G. Arthritis and Rheum. 38, 306-314.

Kishimoto T (1989). The biology of interleukin-6. Blood 74: 1-10.

Kisielow P and Von Boehmer H (1995). Development and selection of T cells: facts and puzzles. Adv. Immunol. 58, 87-209.

Klaus SJ, Sidorenko SP and Clark EA (1996). CD45 ligation induces programmed cell death in T and B lymphocytes. J. Immunol. 156, 2743-2753.

Klausner RD and Samelson LE (1991). T cell antigen receptor activation pathways: The tyrosine kinase connection. Cell 64, 875-878.

Klein G (1968). Tumor-specific transplantation antigens: G. H. A. Clowes memorial lecture.

Cancer Res. 28, 625-35.

Klein E, Klein G, Nadkarni J, Nadkarni JJ, Wigzell H and Clifford P (1968). Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 28, 1300-1310.

Knuth A, Wölfel T and Meyer K-H (1991). Cellular and humoral immune responses against cancer: implication for cancer vaccines. Current Opin. Immunol. 3, 659-664.

Ko HS, Fu SM, Winchester RJ, Yu DT and Kunkel HG (1979). Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells. J. Exp. Med. 150, 246-255.

Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B and Trinchieri G (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827-845.

Koch N and Stockinger B (1991). Molecules that modify antigen recognition. Curr. Opin. Immunol. 3, 10-15.

Koizumi H, Liu C-C, Zheng LM, Joag SV, Bayne NK, Holoshitz J and Young D-E (1991). Expression of perforin and serine esterases by human $\gamma\delta$ T cells. J. Exp. Med. 173, 499-502.

Köhler G and Milstein C (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497.

Kos FJ and Engleman EG (1995). Requirement for natural killer cells in the induction of cytotoxic T cells. J. Immunol. 155, 578-584.

Koyasu S, McConkey DJ, Clayton LK, Abraham S, Yandava B, Katagiri T, Moingeon P, Yamamoto T and Reinherz EL (1992). Phosphorylation of multiple CD3 ϵ tyrosine residues leads to formation of pp21 *in vitro* and *in vivo*. J. Biol. Chem. 267, 3375-3381.

Kranz DM, Patrick TA, Brigle KE, Spinella MJ and Roy EJ (1995). Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc. Natl. acad. Sci. USA 92, 9057-9061.

Krähenbühl O, Rey C, Jenne D, Lanzavecchia A, Groscurth P, Carrel S and Tschopp J (1988). Characterization of granzyme A and B isolated from granules of cloned human cytotoxic T lymphocytes. J. Immunol. 141, 3471-3477.

Krause D, Shearman C, Lang W, Kanzy EJ and Kurrle R (1990). Determination of affinities of murine and chimeric anti α/β -T-cell receptor antibodies by flow cytometry. Berhing Inst. Mitt. 87, 56-67.

Kriegler M, Perez C, DeFay K, Albert I and Lu SD (1988). A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53, 45-53.

Kripke ML (1981). Immunologic mechanisms in UV radiation carcinogenesis. Adv. Cancer Res. 34, 69-106.

Kroesen BJ, Buter J, Sleijfer DT, Janssen RAJ, van der Graaf TH, de Leij L and Mulder NH (1994). Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer 70, 652-661.

Kruse J, Mailhammer R, Wernecke H, Faissner A,

Sommer I, Goridis C and Schachner M (1984). Neural cell adhesion molecules and myelin-associated glycoprotein share a common carbohydrate moiety recognized by monoclonal antibodies L2 and HNK-1. Nature 311, 153-155.

Kuge S., Miura Y, Nakamura Y, Miotomi T, Habu S and Nishimura T (1995). Superantigen-induced human CD4⁺ helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy. J. Immunol. 154, 1777-1785.

Kummer JA, Kamp AM, Tadema TM, Vos W, Meijer CJLM and Hack CE (1995). Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood. Clin. Exp. Immunol. 100, 164-172.

Kung P, Goldstein G, Reinherz EL and Schlossman SF (1979). Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206, 347-349.

Kurrle R, Seyfert W, Trautwein A and Seiler FR (1985). Cellular mechanism of T cell activation by modulation of the T3 antigen complex. Transplantation Proc. 13, 880-885.

Lamers CHJ, Van De Griend RJ, Braakman E, Ronteltap CPM, Bénard J, Stoter G, Gratama JW and Bolhuis RLH (1992). Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int. J. Cancer 51, 973-979.

Lamont AG and Adorini L (1996). IL-12: a key cytokine in immune regulation. Immunol. Today 17, 214-217.

Lancki DW, Weiss A and Fitch FW (1987). Requirements for triggering of lysis by cytolytic T lymphocyte clones. J. Immunol. 138, 3646-3653.

Lancki DW, Hsieh C-S and Fitch FW (1991). Mechanisms of lysis by cytotoxic T lymphocyte clones. Lytic activity and gene expression in cloned antigen-specific CD4⁺ and CD8⁺ T lymphocytes. J. Immunol. 146, 3242-3249.

Lanier LL and Loken MR (1984). Human lymphocyte subpopulations identified by using three-color immunofluorescence and flow cytometry analysis: correlation of Leu-2, Leu-3, Leu-7, Leu-8, and Leu-11 cell surface antigen expression. J. Immunol. 132, 151-159.

Lanier LL, Le AM, Civin CI, Loken MR and Phillips JH (1986)^a.

The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.
J. Immunol. 136, 4480-448.

Lanier LL, Cwirla S, Federspiel N and Phillips JH (1986)^b.

Human natural killer cells isolated from peripheral blood do not rearrange T cell antigen receptor β chain genes.
J. Exp. Med. 163, 209-214.

Lanier LL (1993).

Distribution and function of lymphocyte surface antigens. Molecules costimulating T lymphocyte activation and effector function.
Ann. NY Acad. Sci. 677, 86-93.

Lanzavecchia A and Scheidegger D (1987).

The use of hybrid hybridomas to target human cytotoxic T lymphocytes.
Eur. J. Immunol. 17, 105-111.

Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC (1994).

Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE.
Nature 371, 346-347.

Lea T, Vartdal F, Davies C and Ugelstad J (1985).
Magnetic monosized polymer particles for fast

and specific fractionation of human mononuclear cells.

Scand. J. Immunol. 22, 207-216.

Lea T, Smeland E, Funderud S, Vartdal F, Davies C, Beiske K and Ugelstad J (1986).

Characterization of human mononuclear cells after positive selection with immunomagnetic particles.
Scand. J. Immunol. 23, 509-519.

Ledbetter JA, June CH, Martin PJ, Spooner CE, Hansen JA and Meier KE (1986).

Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
J. Immunol. 136, 3945-3952.

Ledbetter JA, June CH, Grosmaire LS and Rabinovitch PS (1987).

Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes.
Proc. Natl. Acad. Sci. USA 84, 1384-1388.

Lee KH, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, Benjamin R, Levitt D and Gutterman J (1989).

Concomitant administration of recombinant human interleukin-2 and recombinant interferon α -2A in cancer patients: A phase I study.

J. Clinical Oncol. 7, 1726-1732.

Lee WT and Vitetta ES (1990).

Limiting dilution analysis of CD45R^{hi} and CD45R^{lo} T cells: Further evidence that CD45R^{lo} cells are memory cells.
Cell. Immunol. 130, 459-471.

Lenschow DJ, Walunas TL and Bluestone JA (1996).

CD28/B7 system of T cell costimulation.
Ann. Rev. Immunol. 14, 233-258.

Leo O, Foo M, Sachs DH, Samelson LE and Bluestone JA (1987).

Identification of a monoclonal antibody specific for a murine T3 polypeptide.
Proc. Natl. Acad. Sci. USA 84, 1374-1378.

Leeuwenberg JFM, Spits H, Tax WJM and Capel PJA (1985).

Induction of nonspecific cytotoxicity by monoclonal anti-CD3 antibodies.
J. Immunol. 134, 3770-3775.

Leeuwenberg JFM, Lems SPM and Capel PJA (1987).

Anti-T3 induced cytotoxicity: the role of target cell Fc-Receptors in the lysis of autologous monocytes and the Fc-independent lysis of T3-positive target cells.
Transplant. Proc. 19, 428-431.

Lewis GD, Aggarwal BB, Eessalu TE, Sugarman BJ and Shepard HM (1987).

Modulation of the growth of transformed cells by human tumor necrosis factor- α and interferon- γ . Cancer Res. 47, 5382-5385.

Lewis RS and Cahalan MD (1995). Potassium and calcium channels in lymphocytes. Annu. Rev. Immunol. 13, 623-653.

Lichtenheld MG, Olsen KJ, Lowrey PDM, Hameed A, Hengart H and Podack ER (1988). Structure and function of human perforin. Nature 335, 448-451.

Linsley PS and Ledbetter JA (1993). The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11, 191-212.

Liu C-C, Detmers PA, Jiang S and Young JD-E (1989)^a. Identification and characterization of a membrane-bound cytotoxin of murine cytolytic lymphocytes that is related to tumor necrosis factor/cachectin. Proc. Natl. Acad. Sc. USA 86, 3286-3290.

Liu C-C, Rafii S, Granelli-Piperno A, Trapani JA and Young JD-E (1989)^b. Perforin and serine esterase gene expression in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J. Exp. Med. 170, 2105-2118.

Liu C-C, Walsh CM and Young JD-E (1995). Perforin: structure and function. Immunol. Today 16, 194-201.

Ljunggren HG and Kärre K (1990). In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11, 237-244.

Lobo PI and Patel HC (1994). A novel role for MHC class II antigens: Evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells. Immunol. 83, 240-244.

Loetscher H, Pan Y-C E, Lahm H-W, Gentz R, Brockhaus M, Tabuchi H and Lesslauer W (1990). Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61, 351-359.

Lombardi G, Sidhu S, Batchelor R and Lechler R (1994). Anergic T cells as suppressor cells in vitro. Science 264, 1587-1589.

Lonberg N, Taylor LD, Harding FA, Troustine M, Higgins KM, Schramm SR, Kuo C-C, Mashayekh R, Wymore K, McCabe JG, Munoz-O'Regan D, O'Donnell SL, Lapachet ESG, Bengoechea T, Fishwild DM, Carmack CE, Kay RM and Huszar D (1994). Antigen-specific human antibodies from mice

comprising four distinct genetic modifications. Nature 368, 856-859.

London L, Perussia B and Trinchieri G (1986). Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J. Immunol. 137, 3845-3854.

Lopez-Botet M, Moretta L and Strominger J (1996). NK-cell receptors and recognition of MHC class I molecules. Immunol. Today 17, 212-214.

Lopez-Nevot MA, Esteban F, Ferron A, Gutiérrez J, Oliva MR, Romer C, Huelin C, Ruiz-cabello F and Garrido F (1989). HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br. J. Cancer 59, 221-226.

Lorenzen J, Lewis CE, McCracken D, Horak E, Greenall M and McGee JOD (1991). Human tumour-associated NK cells secrete increased amounts of interferon- γ and Interleukin-4. Br. J. Cancer 64, 457-462.

Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, Droge W, Krammer

PH, Fiers W and Schulze-Osthoff K (1995).

Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis.

Nature 375, 81-83.

Lotze MT, Line BR, Mathisen GJ, Rosenberg SA (1980).

The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors.

J. Immunol. 125: 1487-1493.

Lotze MT and Finn OJ (1990).

Recent advances in cellular immunology: implications for immunity to cancer. Immunol. Today 11, 190-192.

Lovchik JC and Hong R (1977).

Antibody-dependent cell-mediated cytotoxicity (ADCC): analyses and projections.

Progress in Allergy 22, 1-44.

Lovens-De Graef D, Delvenne P, Lelièvre P, Martin-Simonet M-T, Greimers R, Boniver J and Schaaf-Lafontaine N (1993).

Phenotypical and functional analyses of mononuclear cells during rejection of a transplanted murine fibrosarcoma.

Virchows Arch. B Cell Pathol. 64, 335-344.

Lowcry DM, Aebischer T, Olsen K, Lichtenheld

M, Rupp F, Hengartner H and Podack ER (1989).

Cloning, analysis, and expression of murine perforin 1 cDNA, a component of cytolytic T-cell granules with homology to complement component C9.

Proc. Natl. Acad. Sci. USA 86, 247-251.

Lozzio CB and Lozzio BB (1975).

Human chronic myelogenous leukaemia cell line with positive Philadelphia chromosome.

Blood 45, 321-326.

Luton F, Buferne M, Davoust J, Schmitt-Verhulst AM and Boyer C. (1994)

Evidence for protein tyrosine kinase involvement in ligand-induced TCR/CD3 internalization and surface redistribution.

J. Immunol. 153, 63-72.

Lynch DH, Ramsdell F and Alderson MR (1995).

Fas and FasL in the homeostatic regulation of immune responses.

Immunol. Today 16, 569-574.

Mackay CR (1991).

T-cell memory: the connection between function, phenotype and migration pathways.

Immunol. Today 12, 189-192.

Makino M, Sei Y, Arora PK, Morse III HC and Hartley JW (1992).

Impaired calcium mobilization in CD4⁺

and CD8⁺ T cells in a retrovirus-induced immunodeficiency syndrome, murine AIDS. J. Immunol. 149, 1707-1713.

Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M and Eisenback L (1994).

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369, 67-71.

Manyonda IT, Soltys A J and Hay FC (1992).

A critical evaluation of the magnetic cell sorter and its use in the positive and negative selection of CD45R0⁺ cells.

J. Immunol. Methods 149, 1-10.

Marchalonis JJ. (1969).

An enzymic method for the trace iodination of immunoglobulins and other proteins.

Bioch. J. 113, 299-305.

Margolis B, Hu P, Katzav S, Li W, Oliver JM, Ullrich A, Weiss A and Schessinger J (1992).

Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs.

Nature 356, 71-74.

Marvel J, Lighstone E, Samberg NL, Ettinghausen D and Stauss HJ (1991).

The CD45RA molecule is expressed in naive murine CTL precursors but absent in memory and effector CTL.

Int. Immunol. 3, 21-28.

Mauri D, Wyss-Coray T, Gallati H and Pichler WJ (1995).

Antigen-presenting T cells induce the development of cytotoxic CD4⁺ T cells. I. Involvement of the CD80-CD28 adhesion molecules. J. Immunol. 155, 118-127.

McFarland ED, Hurley TR, Pingel JT, Stefton BM, Shaw A and Thomas ML (1993).

Correlation between Src family member regulation by the protein-tyrosine-phosphatase CD45 and transmembrane signaling through the T-cell receptor Proc. Natl. Acad. Sci. USA 90, 1402-1406.

Melief CJM and Kast WM (1991).

T-cell immunotherapy of cancer. Res. Immunol. 142, 425-429.

Melief CJ (1992).

Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58, 143-75.

Merkenschlager M and Beverley PC (1989).

Evidence for differential expression of CD45 isoforms by precursors for memory-dependent and independent cytotoxic responses: human CD8 memory CTLp selectively express CD45RO (UCHL1) Int. Immunol. 1, 450-459.

Merkenschlager M and Fisher AG (1991).

CD45 isoform switching precedes the activation-

driven death of human thymocytes by apoptosis. Int. Immunol. 3, 1-7.

Merrit JE, McCarthy SA, Davies MPA, and Moores KE (1990).

Use of fluo-3 to measure cytosolic Ca²⁺ in platelets and neutrophils. Biochem. J. 269, 513-519.

Mezzanzanica D, Canevari S, Ménard S, Pupa SM, Tagliabue E, Lanzavecchia A and Colnaghi MI (1988).

Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int. J. Cancer 41, 609-615.

Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR Jr, Segal DM and Wunderlich JR (1991).

Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')₂ antibody prolong host survival in a murine xenograft model. Cancer Res. 51, 5716-5721.

Mier JW, Brandon EP, Libby P, Janicka MW and Aronson FR (1989).

Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy. J. Immunol. 143, 2407-2414.

Miltenyi S, Müller W, Weichel W and Rabruch A (1990).

High gradient magnetic cell separation with MACS.

Cytometry 11, 231-238.

Minami Y, Kono T, Yamada K, Kobayashi N, Kawahara A, Perlmutter RM and Taniguchi T (1993).

Association of p56^{lck} with IL-2 receptor β chain is critical for the IL-2 induced activation of p56^{lck}. EMBO J. 12, 759-768.

Minami Y and Taniguchi T (1995).

IL-2 signaling: recruitment and activation of multiple protein tyrosine kinases by the components of the IL-2 receptor. Curr. Opin. Cell Biol. 7, 156-162

Minowada J, Ohnuma T and Moore GE (1972).

Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J. Natl. Cancer Inst. 49, 891-895.

Minta A, Kao JPY and Tsien RY (1989).

Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. J. Biol. Chem. 264, 8171-8178.

Miotti S, Canevari S, Ménard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue

E and Colnaghi MI (1987).

Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.
Int. J. Cancer 39, 297-303.

Miotti S, Alberti S, Facheris P, Mantovani L, Fornaro M, Stella M, Ménard S, Canevari S and Colnaghi MI (1992).
Membrane association and shedding of the GPI-anchored Ca-MOV18 antigen in human ovary carcinoma cells.
Int. J. Cancer 51, 499-505.

Miyazaki T, Kawahara A, Fujii H, Nakagawa Y, Minami Y, Liu Z-J, Oishi I, Silvennoinen O, Witthuhn BA, Ihle JN and Taniguchi T (1994).
Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits.
Science 266, 1045-1046.

Miyazaki T, Liu Z-J, Kawahara A, Minami Y, Yamada K, Tsujimoto Y, Barsoumian EL, Perimutter RM and Taniguchi T (1995).
Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation.
Cell 81, 223-231.

Moingeon P, Chang H-C, Wallner BP, Stebbins C, Frey AZ and Reinherz EL (1989).
CD2-mediated adhesion facilitates T lymphocyte

antigen recognition function.
Nature 339, 312-314.

Moiré N, Calvo C-F, Métivier D, Perrot J-Y, Vaquero C, Hatakeyama M and Senik A (1990).
Role of interleukin 2 receptor β chain in initiating anti-CD3 and interleukin 2-induced proliferation of human resting T cells.
Eur. J. Immunol. 20, 1981-1987.

Moiré N, Rouleau M, Metivier D, Charpentier B, Senik A (1991).
IL-2-R β expression and function within resting CD8⁺ T cells preferentially segregate with the CD45R0⁺ subset.
Eur-Cytokine-Netw 2, 319-327.

Moretta L, Ciccone E, Mingari MC, Biassoni R and Moretta A (1994).
Human natural killer cells: Origin, clonality, specificity, and receptors.
Adv. Immunol. 55, 341-380.

Morita T, Yonese Y and Minato N (1987).
In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma.
J. Natl. Cancer Inst. 78, 441-450.

Mosmann T (1983).
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
J. Immunol. Methods 65, 55-63.

Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL (1986).
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.
J. Immunol. 136, 2348-2357.

Moutschen MP, Baudrihay MF, Greimers R, Franchimont P and Boniver J (1990).
Polyclonal T cell stimulation with an anti-CD3 monoclonal antibody generates cytotoxic effectors different from interleukin-2 activated killer cells.
Int. J. Immunopathol. Pharmacol. 3, 75-93.

Moutschen M, Jacobs N, Hoyoux C, Martin-Simonet M-T, Schaaf-Lafontaine N and Boniver J (1994).
Presence of $\gamma\delta$ TcR⁺ Tumor infiltrating lymphocytes (TILs) in one case of pediatric Osteogenic sarcoma.
Int. J. Ped. Hematol. Oncol. 1, 277-281.

Mueller DL and Jenkins MK (1995).
Molecular mechanisms underlying functional T-cell unresponsiveness.
Current Opin. Immunol. 7, 375-381.

Mulé JJ, McIntosh JK, Jablons DM and Rosenberg SA (1990).
Antitumor activity of recombinant interleukin 6 in mice.
J. Exp. Med. 171, 629-636.

Muraguchi A, Kishimoto T, Miki Y, Kiaritani T, Kaieda T, Yoshizaki K and Yamamura Y (1981). T cell-replacing factor-(TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J. Immunol. 127, 412-413.

Nagata S and Golstein P (1995). The Fas death factor. Science 267, 1449-56.

Nagler A, Lanier LL and Phillips JH (1990). Constitutive expression of high affinity interleukin 2 receptors on human CD16⁻ natural killer cells in vivo. J. Exp. Med. 171, 1527-1533.

Nakajima F, Khanna A, Xu G, Lagma M, Haschemeyer R, Mouradian J, Wang JC, Stenzel KH, Rubin AL and Suthanthiran M (1994). Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. Proc. Natl. Acad. Sci. USA 91, 7889-7893.

Nakajima H, Tomiyana H and Tokiguchi M (1995). Inhibition of $\gamma\delta$ T cell recognition receptors for MHC class I molecules. J. Immunol. 155, 4139-4142.

Nakarai T, Robertson MJ, Streuli M, WU Z, Ciardelli TL, Smith KA and Ritz J (1994). Interleukin 2 receptor γ chain expression on resting and activated lymphoid cells. J. Exp. Med. 180, 241-245.

Nakata M, Smyth MJ, Norihisa Y, Kawasaki A, Shinkai Y, Okumura K and Yagita H (1990). Constitutive expression of pore-forming protein in peripheral blood γ/δ T cells: Implication for their cytotoxic role in vivo. J. Exp. Med. 172, 1877-1880.

Nakata M, Kawasaki A, Azuma M, Tsuji K, Matsuda H, Shinkai Y, Yagita H and Okumura K (1992). Expression of perforin and cytolytic potential of human peripheral blood lymphocyte subpopulations. Int. Immunol. 4, 1049-1054.

Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ and Lotze MT (1994). Recombinant IL-12 administration induces tumor regression in association with IFN- γ production. J. Immunol. 153, 1697-1706.

Neckers LM and Cossman J (1983). Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required

for DNA synthesis and cell division and is regulated by interleukin 2. Proc. Natl. Acad. Sci. USA 80, 3494-3498.

Nelson BH, Lord JD and Greenberg PD (1994). Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation. Nature 369, 333-336.

Nelson H, Ramsey PS, Kerr LA, McKean DJ and Donohue JH (1990). Regional and systemic distribution of anti-tumor X anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft. J. Immunol. 145, 3507-3515.

Nieto MA, Gonzalez A, Lopez-Rivas A, Diaz-Espada F and Gambon F (1990). IL-2 protects against anti-CD3-induced cell death in human medullary thymocytes. J. Immunol. 145, 1364-1368.

Niklinska BB, Yamada H, O'Shea JJ, June CH, Ashwell JD (1992). Tyrosine kinase-regulated and inositol phosphate Ca^{2+} elevation and mobilization in T cells. J. Biol. Chem. 267, 7154-7159.

Nishimura T, Nakamura Y, Takeuchi Y, Tokeda Y, Iwasawa M, Kawasaki A, Okumura K, Habu S (1992). Generation, propagation, and targeting of human

CD4⁺ helper/killer T cells induced by anti-CD3 monoclonal antibody + recombinant IL-2. An Efficient strategy for adoptive immunotherapy. J. Immunol. 148, 285-291.

Nitta T, Yagita H, Azuma T, Sato K and Okumura K (1989). Bispesific F(ab')₂ monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytotoxicity of human T cells. Eur. J. Immunol. 19, 1437-1441.

Nitta T, Sato K, Yagita H, Okumura K and Ishii S (1990). Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335, 368-371.

North RJ, Awwad M and Dunn PL (1989). The immune response to tumors. Transplantation Proc. 21, 575-577.

Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, Admon A and Crabtree GR (1994). NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 369, 497-502.

Notter M, Ludwig W-D, Bremer S and Thiel E (1993). Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity

Fcγ RI receptor (CD64) on autologous acute myeloid leukemic blast cells. Blood 82, 3113-3124.

Ochoa AC, Gromo G, Alter BJ, Sondel PM and Bach FH (1987). Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, β-IL 1, interferon-γ and -β. J. Immunol. 138, 2728-2733.

Ochoa AC, Hasz DE, Rezonzew R, Anderson PM and Bach FH (1989). Lymphokine-activated Killer activity in long-term cultures with anti-CD3 + interleukin-2: identification and isolation of effector subsets. Cancer Res. 49, 963-968.

O'Garra A and Murphy K (1994). Role of cytokines in determining T-lymphocyte function. Current Opin. Immunol. 6, 458-466.

Ohashi Y, Takeshita T, Nagata K, Mori S and Sugamura K (1989). Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells. J. Immunol. 143, 3548-3555.

Oi VT and Morrison (1986). Chimeric antibodies. Biotechniques 4, 214-221.

Ortaldo JR, Mason A and Overton R (1986).

Lymphokine-activated killer cells. Analysis of progenitors and effectors. J. Exp. Med. 164, 1193-1205.

Ostensen ME, Thiele DL and Lipsky PE (1987). Tumor necrosis factor-α enhances cytolytic activity of human natural killer cells. J. Immunol. 138, 4185-4191.

Otten GR and Germain RN (1991). Split anergy in a CD8⁺ T cell: Receptor-dependent cytotoxicity in the absence of interleukin-2 production. Science 251, 1228-1229.

Owen-Schaub LB, Gutterman JU and Grimm EA (1988)^a. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: Effect of tumor necrosis factor α and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 48, 788-792.

Owen-Schaub LB, Loudon WG, Yagita M and Grimm EA (1988)^b. Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors. Cell. Immunol. 111, 235-246.

Ozdemirli M, El-Khatib M, Bastiani L, Akdeniz H, Kuchroo V and Ju S-T (1992). The cytotoxic process of CD4 Th1 clones.

J. Immunol. 149, 1889-1895.

Pantaleo G, Olive D, Poggi A, Pozzan T, Moretta L and Moretta A (1987).

Antibody-induced modulation of the CD3/T cell receptor complex causes T cell refractoriness by inhibiting the early metabolic steps involved in T cell activation. J. Exp. Med. 166, 619-624.

Palacios R (1985).

Mechanisms by which accessory cells contribute in growth of resting T lymphocytes initiated by OKT3 antibody. Eur. J. Immunol. 15, 645-651.

Pardi R., Bender JR, Dettori C, Giannazza E and Engleman EG (1989). Heterogeneous distribution and transmembrane signaling properties of lymphocyte function-associated antigen (LFA-1) in human lymphocyte subsets. J. Immunol. 143, 3157-3166.

Parmiani G (1990).

An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol. Today 11, 113-115.

Pasternack MS and Eisen NE (1985). A novel serine esterase expressed by cytotoxic T lymphocytes. Nature 314, 743-745.

Pater MM and Pater A. (1985).

Human papillomavirus types 16 and 18 sequences in carcinoma cell lines of the cervix. Virology 145, 313-318.

Paul WE (1991).

Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 77, 1859-1870.

Pellegrini S and Schindler C. (1993).

Early events in signalling by interferons. Trends Biochem. Sci. 18, 338-342.

Perez P, Hoffman RW, Shaw S, Bluestone JA and Segal DM (1985).

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316, 354-356.

Peri KG and Veillette A (1994).

Tyrosine protein kinases in T lymphocytes. Chem. Immunol. Samelson LE (ed) 59, 19-39.

Perkins GR, Flemming CL, Kabat D and Collins MKL (1993).

The role of IL-2 interaction with p75 and p55 receptor molecules in the stimulation of cell proliferation. Int. Immunol. 5, 541-549.

Perlmann P, Perlmann H and Biberfeld P (1972).

Specifically cytotoxic lymphocytes produced by preincubation with antibody-complexed target cells. J. Immunol. 108, 558-561.

Pernis A, Gupta S, Gollob KJ, Garfein E,

Coffman RL, Schindler C and Rothman P (1995).

Lack of interferon γ receptor β chain and the prevention of interferon γ signaling in Th1 cells. Science 269, 245-247.

Pestka S, Langer JA, Zoon KC, Samuel CE (1987).

Interferons and their actions. Annu. Rev. Biochem. 56, 727-777.

Peter HH (1983).

The origin of human NK cells. An ontogenic model derived from studies in patients with immunodeficiencies. Blut 46, 239-245.

Pflueger E, Mueller EA and Anderer FA (1990).

Preservation of cytotoxic function during multi-cycle immunomagnetic cell separations of human NK cells using a new type of magnetic bead. J. Immunol. Methods 129, 165-173.

Phillips JH and Lanier LL (1986).

Dissection of the lymphokine-activated killer cell phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocyte to cytolysis. J. Exp. Med. 164, 814-825.

Phillips JH, Takeshita T, Sugamura K and Lanier LL (1989).

Activation of natural killer cells via the p75 interleukin 2 receptor. J. Exp. Med. 170, 291-296.

Pimentel-Muñoz FX, Muñoz-Fernández MA, Fresno M (1994).

Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines.
J. Immunol. 152, 5714-5722

Platts KE, Lawry J, Hancock BW and Rees RC (1993).

Phenotypic and cell cycle analysis of human peripheral blood mononuclear cells activated with interleukin-2 and/or OKT3.
Exp. Cell Res. 208, 154-160.

Plebanski M, Saunders M, Burtles SS, Crowe S and Hooper DC (1992).

Primary and secondary human *in vitro* T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms.
Immunology. 75, 86-91.

Podack ER, Hengartner H and Lichtenheld M (1991).

A central role of perforin in cytotoxicity?
Ann. Rev. Immunol. 9, 129-157.

Poenie M, Tsien RY and Schmitt-Verhulst A-M (1987).

Sequential activation and lethal hit measured by $[Ca^{2+}]_i$ in individual cytolytic T cells and targets.
EMBO J. 6, 2223-2232.

Pohl C, Denfeld R, Renner C, Jung W, Bohlen H, Sahin U, Hombach A, van Lier R, Schwomzen M, Diehl V

and Pfreundschuh M (1993).

CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of Hodgkin's lymphoma.
Int. J. Cancer 54, 820-827.

Powell LD, Sgroi D, Sjoberg ER, Stamenkovic I and Varki A (1993).

Natural ligands of the B cell adhesion molecule CD22 β carry N-linked oligosaccharides with α -2,6-linked sialic acids that are required for recognition.
J. Biol. Chem. 268, 7019-7027.

Pupa SM, Canevari S, Fontanell R, Ménard S, Mezzanzanica D, Lanzavecchia A and Colnaghi MI (1988).

Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
Int. J. Cancer 42, 455-459.

Pupa SM, Canevari S, Colzani E, Damgard EM, Ménard S, Miotti S and Colnaghi MI (1991).

Purification of bispecific monoclonal antibodies produced by a hybrid hybridoma.
J. Immunol. Res. 3, 16-23.

Qian D, Griswold-Prenner I, Rosner MR and Fitch FW (1993).

Multiple components of the T cell antigen receptor complex become tyrosine-

phosphorylated upon activation.

J. Biol. Chem. 268, 4488-4493.

Qian J-H, Titus JA, Andrew SM,

Mezzanzanica D, Garrido MA, Wunderlich JR and Segal DM (1991).

Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.
J. Immunol. 146, 3250-3256.

Quinones RR, Segal DM, Henkart P, Perez P and Gress RE (1989).

Inhibition of cytotoxic T cell lysis by anti-CD8 monoclonal antibodies: studies with CD3-targeted cytolysis of nominal antigen-negative targets.
J. Immunol. 142, 2200-2206.

Rabinovitch PS, Torres RM, and Engel D (1986).

Simultaneous cell cycle analysis and two-color surface immunofluorescence using 7-amino-actinomycin D and single laser excitation: applications to study of cell activation and the cell cycle of murine LY-1 B cells.
J. Immunol. 136, 2769-2775.

Rammensee H-G, Falk K and Rötzschke O (1993).

MHC molecules as peptide receptors.
Curr. Opin. Immunol. 5, 35-44.

Rasmussen A-M, Smeland EB, Erikstein

BK, Cagnault L and Funderud S (1992).

A new method for detachment of Dynabeads from positively selected B lymphocytes.

J. Immunol. Methods 146, 195-202.

Ravetch JV (1994).

Fc receptors: Rubor redux.

Cell 78, 553-560.

Reed PW and Lardy HA (1972).

A23187: a divalent cation ionophore.

J. Biol. Chem. 247, 6970-6977.

Reilly EB and Antognetti G (1991).

Increased tumor-specific CTL activity in human tumor-infiltrating lymphocytes stimulated with autologous tumor lines.

Cell. Immunol. 135, 526-33.

Reinherz EL, Penta AC, Hussey RE, Schlossman SF (1981).

A rapid method for separating functionally intact human T lymphocytes with monoclonal antibodies.

Clin. Immunol. Immunopathol. 21, 257-66.

Renner C, Jung W, Sahin U, van Lier R and Pfreundschuh M (1995).

The role of lymphocyte subsets and adhesion molecules in Tcell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies.

Eur. J. Immunol. 25, 2027-2033.

Renner C and Pfreundschuh M (1995).

Tumor therapy by immune recruitment with bispecific antibodies.

Immunol. Rev. 145, 179-209.

Reth M (1989).

Antigen receptor tail clue.

Nature 338, 383-384.

Rheinwald JG and Green H (1975).

Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells.

Cell 6, 331-344.

Richards JM, Vogelzang NJ and Bluestone JA (1990).

Neurotoxicity after treatment with muromonab-CD3.

New Eng. J. Med. 323, 7-8.

Riechmann L, Clark M, Waldmann H and Winter G (1988).

Reshaping human antibodies for therapy.

Nature 332, 323-327.

Rigley K, Slocombe P, Proudfoot K, Wahid S, Mandair K and Bebbington C (1995).

Human p59^{fyn}(T) regulates OKT3-induced calcium influx by a mechanism distinct from PIP₂ hydrolysis in Jurkat T cells.

J. Immunol. 154, 1136-1145.

Rinnoy Kan EA, Wright SD, Welte K and Wang CY (1986).

Fc receptors on monocytes cause OKT3 treated lymphocytes to

internalize T3 and to secrete IL-2.

Cell. Immunol. 98, 181-187.

Robbins PA, Maino VC, Warner NL and Brodsky FM (1988).

Activated T cells and monocytes have characteristic patterns of class II antigen expression.

J. Immunol. 141, 1281-1287.

Roberts K, Lotze MT and Rosenberg SA (1987).

Separation and functional studies of the human lymphokine-activated killer cell.

Cancer Res. 47, 4366-4371.

Robey E and Allison JP (1995).

T-cell activation: Integration of signals from the antigen receptor and costimulatory molecules.

Immunol. Today 16, 306-309.

Robins RA and Baldwin RW (1985).

T-cell subsets in tumour rejection responses.

Immunol. Today 6, 55-58.

Roder J and Duwe A (1979).

The beige mutation in the mouse selectively impairs natural killer cell function.

Nature 278, 451-453.

Romagnani S (1994).

Lymphokine production by human T cells in disease states.

Ann. Rev. Immunol. 12, 227-257.

Roosnek EE, Van Lier RA and Aarden LA (1987).

Two monoclonal anti-CD3 antibodies can induce different events in human T lymphocyte activation.

Eur. J. Immunol. 17, 1507-1510.

Roosnek E and Lanzavecchia A (1989).

Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell.

J. Exp. Med. 170, 297-302.

Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K and Mark DF (1984).

Biological activity of recombinant human interleukin-2 produced in *Escherichia coli*.

Science 223, 1412-1415.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C and Reichert CM (1985).

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

New Eng. J. Med. 313, 1485-1492.

Rosenberg SA, Spiess P and Lafreniere R (1986).

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Science 233, 1318-1321.

Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JG, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP and White DE (1988).

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.

New Eng. J. Med. 319, 1676-1680.

Rosenberg SA (1992).

The immunotherapy and gene therapy of cancer.

J. Clin. Oncol. 10, 180-199.

Rosenfeld MA,

Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L, Perricaudet M, Guggino WB, Pavirani A, Lecocq J-P and Crystal RG (1992).

In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

Cell 68, 143-155.

Rosenstein M, Yron I, Kaufmann Y and Rosenberg SA (1984).

Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Cancer Res. 44, 1946-1953.

Rouvier E, Luciani M-F and Golstein P (1993).

Fas involvement in Ca²⁺-independent T cell-mediated cytotoxicity.

J. Exp. Med. 177, 195-200.

Russell JH, White CL, Loh DY and Meleedy-Rey P (1991).

Receptor-stimulated death pathway is opened by antigen in mature T cells.

Proc. Natl. Acad. Sci. USA 88, 2151-2155.

Russell JH and Wang R (1993).

Autoimmune *gld* mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells.

Eur. J. Immunol. 23, 2379-2382.

Russell SM, Johnston JA, Noguchi M, Kawamura M, Bacon CM, Friedmann M, Berg M, McVicar DW, Witthuhn BA, Silvennoinen O, Goldman AS, Shmalstieg FC, Ihle JN, O'Shea JJ and Leonard WJ (1994).

Interaction of IL-2R β and γ c chains with Jak1 and Jak3: Implications for XSCID and XCID.

Science 266, 1042-1044.

Sagerström CG, Kerr EM, Allison JP and Davis MM (1993).

Activation and differentiation requirements of primary T cells in vitro.

Proc. Natl. Acad. Sci. USA 90, 8987-8991.

Sakihama T, Smolyar A and Reinherz EL (1995).

Molecular recognition of antigen involves lattice formation between CD4,

MHC class II and TCR molecules.
Immunol. Today 16, 581-587.

Samelson LE, Patel MD, Weissman AM, Harford JB and Klausner RD (1986).

Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor.
Cell 46, 1083-1090.

Samelson LE and Klausner RD (1992).

Tyrosine kinases and tyrosine-based activation motifs. Current research on activation via the T cell antigen receptor.
J. Biol. Chem. 267, 24913-24916.

Salmeron A, Sanchez-Madrid F, Ursa MA, Fresno M and Alarcon B (1991).

A conformational epitope expressed upon association of CD3- ϵ with either CD3- δ or CD3- γ is the main target for recognition by anti-CD3 monoclonal antibodies.

J. Immunol. 147, 3047-3052.

Sancho J, Ledbetter JA, Choi M-S, Kanner SB, Deans JP and Terhorst C (1992).

CD3- ζ surface expression is required for CD4-p56^{lck}-mediated up-regulation of T cell antigen receptor-CD3 signaling in T Cells.

J. Biol. Chem. 267, 7871-7879.

Sancho J, Franco R, Chatila T, Hall C and Terhorst C (1993).

The T cell receptor associated CD3- ϵ protein is phosphorylated upon T cell activation in the two tyrosine residues of a conserved signal transduction motif.

Eur. J. Immunol. 23, 1636-1642.

Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA and Shaw S (1988).

Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2 and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN- γ production.

J. Immunol. 140, 1401-1407.

Sanders ME, Makgoba MW, June CH, Young HA and Shaw S (1989).

Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation.

Eur. J. Immunol. 19, 803-808.

Sano S, Kiyotaki C, Tatsumi Y-I, Fujiwara H and Hamaoka T (1989).

Cytotoxic T lymphocyte unresponsiveness induced by prolonged treatment with immobilized anti-CD3 antibody. Association of impairment of cytolytic activity with temporary depletion of intracellular protein Kinase C.

J. Immunol. 143, 2797-2805.

Scatchard G (1949).

The attraction of proteins for small molecules and ions.

Ann N.Y. Acad. Sci. 51, 660-672.

Schaaf-Lafontaine N (1978).

Separation of lymphoid cells with a suppressor effect on the activity of cytotoxic cells in vitro during the growth of a syngeneic mouse tumour.

Int. J. Cancer 21, 329-333.

Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GHW, Gatanaga T, Granger GA, Lentz R, Raab H, Kohr WJ and Goeddel DV (1990).

Molecular cloning and expression of a receptor for human tumor necrosis factor.

Cell 61, 361-370.

Scheurich P, Thoma B, Ucer U and Pfizenmaier K (1987).

Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)- α : induction of TNF receptors on human T cells and TNF- α -mediated enhancement of T cell responses.

J. Immunol. 138, 1786-1790.

Schild H, Mavaddat N, Litzberger C, Ehrlich EW, Davis MM, Bluestone JA, Matis L, Draper RK and Chien Y-H (1994).

The nature of major histocompatibility complex recognition by $\gamma\delta$ T cells.

Cell 76, 29-37.

Schlitt HJ, Kurrie R and Wonogit K (1989).

T cell activation by monoclonal antibodies

directed to different epitopes on the human T cell receptor/CD3 complex: evidence for two different modes of activation.

Eur. J. Immunol. 19, 1649-1655.

Schrezenmeier H, Kurrle R, Wagner H and Fleischer B (1985).

Activation of human T lymphocytes. III. Triggering of bystander cytotoxicity in cytotoxic T cell clones by antibodies against the T3 antigen or by a calcium ionophore.

Eur. J. Immunol. 15, 1019-1024.

Schulze-Osthoff K, Krammer PH and Dröge W (1994).

Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death.

EMBO J. 13, 4587-4596.

Schwab R, Crow MK, Russo C and Weksler ME (1985).

Requirements for T cell activation by OKT3 monoclonal antibody: role of modulation of T3 molecules and interleukin 1.

J. Immunol. 135, 1714-1718.

Schwartz RH (1990).

A cell culture model for T lymphocyte clonal anergy. Science 248, 1349-1356.

Schwartz RH (1992).

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

Cell 71, 1065-1068.

Schwartzentruber DJ, Topalian SL, Mancini M and Rosenberg SA (1991).

Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation.

J. Immunol. 146, 3674-3681.

Schwartzentruber DJ, Stetler-Stenvenson M, Rosenberg SA and Topalian SL (1993).

Tumor-infiltrating lymphocytes derived from selected B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor- α in response to autologous tumor stimulation.

Blood 82, 1204-1211.

Schwitzer R, Franklin RA, Domenico J, Renz H and Gelfand EW (1992).

Monoclonal antibodies directed to different epitopes in the CD3-TCR complex induce different states of competence in resting human T cells.

J. Immunol. 148, 1322-1328.

Sciammas R, Johnson RM, Sperling AI, Brady W, Linsley PS, Spear PG, Fitch FW and Bluestone JA (1994).

Unique antigen recognition by a herpesvirus-specific TCR- $\gamma\delta$ cell.

J. Immunol. 152, 5392-5397.

Scott P (1993).

IL-12: Initiation cytokine for cell-mediated immunity.

Science 260, 496-497.

Seder RA and Paul WE (1994).

Acquisition of lymphokine-producing phenotype by CD4⁺ T cells.

Ann. Rev. Immunol. 12, 635-673.

Sefton BM and Taddie JA (1994).

Role of tyrosine kinases in lymphocytes activation. Current Opin. Immunol. 6, 372-379.

Segal DM and Snider DP (1989).

Targeting and activation of cytotoxic lymphocytes. Chem Immunol. 47, 179-213.

Segal DM, Qian J-H, Titus JA, Moreno B, George AJT, Jost CR, Kurucz I, El-Gamil M and Wunderlich JR (1992).

Targeted cytokine production. Int. J. Cancer Suppl. 7, 36-38.

Sei Y and Arora PK (1991).

Quantitative analysis of calcium (Ca²⁺) mobilization after stimulation with mitogens or anti-CD3 antibodies. Simultaneous fluo-3 and immunofluorescence flow cytometry.

J. Immunol. Methods 137, 237-244.

Sgroi D, Varki A, Braesch-Andersen S and Stamenkovic I (1993).

CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J. Biol. Chem. 268, 7011-7018.

Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PCL, Feldmann M and Carter P (1992).

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 175, 217-225.

Shapiro HM (1995). Practical flow cytometry. Third edition. Wiley-Liss

Shaw AS, Chalupny J, Whitney JA, Hammond G, Amrein KE, Kavathas P, Sefton BM and Rose JK (1990). Short related sequences in the cytoplasmic domains of CD4 and CD8 mediate binding to the amino-terminal domain of the p56^{lck} tyrosine kinase. Mol. Cell. Biol. 10, 1853-1862.

Shi L, Nishiota WK, Th'ng J, Bradbury EM, Litchfield DW and Greenberg AH (1994). Premature p34cdc2 activation required for apoptosis. Science 263, 1143-1145.

Shinkai Y, Takio K and Okumura K (1988). Homology of perforin to the ninth component of complement (C9). Nature 334, 525-527.

Shinkai Y, Rathbun G, Lam K-P, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM and Alt FW (1992). RAG-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68: 855-867.

Shresta S, Heusel JW, Macivor DM, Wesselschmidt RL, Russel JH, and Ley TJ (1995). Granzyme B plays a central role in cytotoxic lymphocyte-induced apoptosis. Immunol. Rev. 146, 211-221.

Shuai K, Horvath CM, Huang LHT, Qureshi SA, Cowburn D and Darnell JE (1994). Interferon activation of the transcription factor Stat91 involves dimerization through SH2-Phosphotyrosyl peptide interactions. Cell 76, 821-828.

Si L and Whiteside TL (1983). Tissue distribution of human NK cells studied with anti-Leu-7 monoclonal antibody. J. Immunol. 130, 2149-2155.

Smith CA, Williams GT, Kingston R, Jenkinson EJ and Owen JJT (1989). Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 337, 181-184.

Smyth MJ, Norihisa Y and Ortaldo JR (1992). Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets. J. Immunol. 148, 55-62.

Smyth MJ and Trapani JA (1995). Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol. Today 16, 202-206.

Sondel PM, Hank JA, Kohler PC, Chen BP, Minkoff DZ and Molenda JA (1986). Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J. Immunol. 137: 502-511.

Spero L and Metzger JF (1981). Staphylococcal enterotoxin A (SEA). Meth. Enzymol. 78, 331-336.

Srivastava PK, deleo AB and Old LJ (1986). Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sc. USA 83, 3407-3411.

Staerz UD and Bevan MJ (1985). Cytotoxic T lymphocyte-mediated lysis via the Fc receptor of target cells. Eur. J. Immunol. 15, 1172-1177.

Stamenkovic I, Sgroi D, Aruffo A, Sy MS and Anderson T (1991). The B lymphocyte adhesion molecule CD22 interacts with leukocyte

common antigen CD45R0 on T cells and α 2-6 sialytransferase, CD75, on B cells.
Cell 66, 1133-1144.

Stankova J, Hoskin DW and Roder JC (1989). Murine anti-CD3 monoclonal antibody induces potent cytolytic activity in both T and NK cell populations.
Cell. Immunol. 121, 13-29.

Steen HB (1990). Characteristics of flow cytometers.
In: "Flow Cytometry and sorting", pp 11-26; Melamed MR, Lindmo T and Mendelsohn ML Edts, Wiley-Liss, NY.

Steger GG, Pierce WC, Figlin R, Czernin J, Kaboo R, deKernion JB, Okarma T and Belldegrun A (1994). Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
Clin. Immunol. Immunother. 72, 237-247.

Street NE, Schumacher JH, Fong TAT, Bass H, Fiorentino DF, Leverah JA and Mosmann TR (1990). Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells.

J. Immunol. 144,1629-1639.

Suda T, Takahashi T, Golstein P and Nagata S (1993). Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.
Cell 75, 1169-1178.

Suda T and Nagata S (1994). Purification and characterization of the Fas-ligand that induces apoptosis.
J. Exp. Med. 179, 873-879.

Suhrbier A, Fernan A, Burrows SR, Saul A and Moss DJ (1991). BLT esterase activity as an alternative to chromium release in cytotoxic T cell assays.
J Immunol Methods 145, 43-53

Sundström C and Nilsson K (1976). Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17, 565-577.

Taga K, Kasahara Y, Yachie A, Miyawaki T and Taniguchi N (1991). Preferential expression of IL-2 receptor subunits on memory populations within CD4⁺ and CD8⁺ T cells.
Immunology. 72, 15-19.

Takahashi T, Ishikura H, Iwai K, Takahashi C, Kato H, Tanabe T and Yoshiki T (1993). Cytokine regulation of cell-to-cell interactions in

lymphokine-activated killer cell cytotoxicity in vitro.
Cancer Immunol. Immunother. 36, 76-82.

Takeshita T, Goto Y, Tada K, Nagata K, Asao H and Sugamura K (1989). Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor.
J. Exp. Med. 169, 1323-1332.

Talento A, Nguyen M, Law S, Wu JK, Poe M, Blake JT, Patel M, Wu T-J, Manyak CL, Silberklang M, Mark G, Springer M, Sigal NH, Weissman IL, Bleackley RC, Podack ER, Tykocinski ML and Koo GC (1992). Transfection of mouse cytotoxic T lymphocyte with an antisense granzyme A vector reduces lytic activity.
J. Immunol. 149, 4009-4015.

Tao M-H and Levy R (1993). Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
Nature 362, 755-758.

Tartaglia LA, Ayres TM, Wong GHW and Goeddel DV (1993). A novel domain within the 55 kd TNF receptor signals cell death.
Cell 74, 845-853.

Tax WJM, Willems HW, Reekers PPM, Capel PJA and Koene RAP (1983).

Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature 304, 445-447.

Taylor J, Trimarchi C, Weinberg R, Languet B, Guillemin F, Desmettre P and Paoletti E (1991). Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 9, 190-193.

Telerman A, Amson RB, Romasco F, Wybran J, Galand P and Mosselmans R (1987). Internalization of human T lymphocytes receptors. Eur. J. Immunol. 17, 991-997.

Terstappen LWMM, Huang S and Picker LJ (1992). Flow cytometric assessment of human T-cell differentiation in thymus and bone marrow. Blood 79, 666-677.

Testi R, D'Ambrosio D, De Maria R and Santoni A (1994). The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol. Today 15, 479-483.

Thiele DL, Patel SS and Lipski PE (1988). Anti-CD3 and phorbol myristate acetate regulation of MHC unrestricted T cell cytotoxicity. Lack of a requirement for CD3/T cell receptor complex expression during tumor cell lysis. J. Immunol. 140, 3253-3260.

Ting C-C, Hargrove M and Yun YS (1988). Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. J. Immunol. 141, 741-748.

Ting C-C, Hargrove ME, Wang J and Patel AD (1995). Differential requirement of protein tyrosine kinase and protein kinase C in the generation of IL-2-induced LAK cell and α CD3-induced CD3-AK cell responses. Cell. Immunol. 160, 286-296.

Titus JA, Garrido MA, Hecht TT, Winkler DF, Wunderlich JR and Segal DM (1987). Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice. J. Immunol. 138, 4018-4022.

Tomazic VJ, Farha M, Loftus A and Elias EG (1988). Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro. J. Immunol. 140, 4056-4061.

Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y and Rosenberg SA (1994). Human CD4⁺ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

Proc. Natl. Acad. Sc. USA 91, 9461-9465.

Torimoto Y, Rothstein DM, Dang NH, Schlossman SF and Morimoto C (1992). CD31, a novel cell surface marker for CD4 cells of suppressor lineage, unaltered by state of activation. J. Immunol. 148, 388-396.

Tovar Z, Dauphinée M and Talal N (1988). Synergistic interaction between anti-CD3 and IL-2 demonstrated by proliferative response, interferon production, and non-MHC-restricted killing. Cell. Immunol. 117, 12-21.

Trapani JA, Klein JL, White PC and Dupont B (1988). Molecular cloning of an inducible serine esterase gene from human cytotoxic lymphocytes. Proc. Natl. Acad. Sci. USA 85, 6924-6928.

Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin K-M and Krammer PH (1989). Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-304.

Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, van Pel A, De Plaen E, Amar-Costesec A and Boon T (1992). A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T

lymphocytes directed against tumor antigen MZ2-E.
J. Exp. Med. 176, 1453-1457.

Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Sehra J, London L and Perussia B (1984).
Response of resting human peripheral blood natural killer cells to interleukin 2.
J. Exp. Med. 160, 1147-1169.

Trinchieri G (1989).
Biology of natural killer cells.
Adv. Immunol. 47, 187-376.

Trinchieri G (1994).
Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.
Blood 84, 4008-4027.

Triozzi PL, Eicher DM, Smoot J and Rinehart JJ (1992).
Modulation of leukemic cell sensitivity to lymphokine-activated killer cytotoxicity: role of intercellular adhesion molecule-1.
Exp. Hematol. 20, 1072-1076.

Trowbridge IS (1994).
CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development.
Ann. Rev. Immunol. 12: 85-116.

Tsien RY, Pozzan T and Rink TJ (1982).
Calcium homeostasis in intact lymphocytes: Cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator.
J. Cell Biol. 94, 325-334.

Tsien R and Pozzan T (1989).
Measurement of cytosolic free Ca^{2+} with quin2.
Method. Enzymol. 172, 230-262.

Tsuda M., Kitamura F. and Miyasaka M (1989).
Characterization of the interleukin 2 receptor β chain using three distinct monoclonal antibodies.
Proc. Natl. Acad. Sc. USA 86, 1982-1986

Tunnacliffe A, Olsson C and de la Hera A (1989).
The majority of human CD3 epitopes are conferred by the epsilon chain.
Int. Immunol. 1, 546-550.

Tutt A, Greenman J, Stevenson GT and Glennie MJ (1991).
Bispecific F(ab' γ)₃ antibody derivatives for redirecting unprimed cytotoxic T cells.
Eur. J. Immunol. 21, 1351-1358.

Tutt MM, Schuler W, Kuziel WA, Tucker PW, Bennett M, Bosma MJ and Kumar V (1987).
T cell receptor genes do not rearrange or express functional transcripts in natural killer cells of scid mice.
J. Immunol. 138, 2338-2344.

Ucker DS, Meyers J and Obermiller PS (1992).
Activation-driven T cell death.
II. Quantitative differences alone distinguish stimuli triggering nontransformed T cell proliferation or death.
J. Immunol. 149, 1583-1592.

Unutmaz D, Pileri P and Abrignani S (1994).
Antigen-independent activation of naive and memory resting T cells by a cytokine combination.
J. Exp. Med. 180, 1159-1164.

Valentin H, Groux H, Gelin C, Chretien I and Bernard A (1990).
Modulation of lymphokine release and cytolytic activities by activating peripheral blood lymphocytes via CD2.
J. Immunol. 144, 875-882.

Vandenberghe PA and Ceuppens JL (1990).
Flow cytometric measurement of cytoplasmic free calcium in human peripheral blood T lymphocytes with fluo-3 a new fluorescent calcium indicator.
J. Immunol. Methods 127, 197-205.

van den Broek MF, Kagi D, Zinkernagel RM and Hengartner H (1995).
Perforin dependence of natural killer cell-mediated tumor control in vivo.
Eur. J. Immunol. 25, 3514-3516.

Van den Eynde B and Brichard VG (1995).
New tumor antigens recognized by T cells.
Current Opin. Immunol. 7, 674-681.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, Knuth A and Boon T (1991).
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
Science 254, 1643-1647

Van Pel A, Vessière F and Boon T (1983).
Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis.
J. Exp. Med. 157, 1992-2001.

Van Pel A, Van der Bruggen P, Coulie PG, Brichard VG, Lethé B, Van den Eynde B, Uyttenhove C, Renauld J-C and Boon T (1995).
Genes coding for tumor antigens recognized by cytolytic T lymphocytes.
Immunol. Rev. 145, 229-250.

van Ravenswaay Claasen HH, van de Griend RJ, Mezzanzanica D, Bolhuis RLH, Warnaar SO and Fleuren GJ (1993).
Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3.
Int. J. Cancer 55, 128-136.

van Seventer GA, Shimizu Y and Shaw S (1991).
Roles of multiple accessory molecules in T-cell activation.
Current Opin. Immunol. 3, 294-303.

Van Wauwe JP, De Mey JR and Goossens JG (1980).
OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.
J. Immunol. 124: 2708-2713.

Vassalli P (1992).
The pathophysiology of tumor necrosis factors.
Annu. Rev. Immunol. 10, 411-452.

Veillette A, Bookman MA, Horak EM, Samelson LE and Bolen JB (1989).
Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56^{lck}.
Nature 338, 257-259

Versteeg R (1992).
NK cells and T cells: mirror images.
Immunol. Today 13, 244-247.

Verwilghen J, Baroja ML, Van Vaeck F, Van Damme J and Ceuppens JL (1991).
Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation.
Immunology 72, 269-276.

Vignaux F and Golstein P (1994).
Fas-based lymphocytes-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway?
Eur. J. Immunol. 24, 923-927.

Vose BM and Moore M (1985).
Human tumor infiltrating lymphocytes: a marker of host response.
Sem. Hematol. 22, 27-40.

Voss SD, Sondel PM and Robb RJ (1992).
Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: Association of the p64 IL-2R γ chain with the IL-2R β chain in functional intermediate-affinity IL-2R.
J. exp. Med. 176, 531-541.

Vose BM and Moore M (1985).
Human tumor infiltrating lymphocytes: a marker of host response.
Sem. Hematol. 22, 27-40.

Walker C, Pichler WJ, Koponen M, Domzig W and De Weck AL (1986).
Different effects of IL-2 addition or antibody crosslinking on T-cell subset stimulation by CD3 antibodies.
Cell. Immunol. 101, 195-203.

Wang ECY, Lehner PJ, Graham S and Borysiewicz LK (1994).
CD8^{high} (CD57⁺) T cells in normal, healthy individuals specifically

suppress the generation of cytotoxic T lymphocytes to Epstein-Barr virus transformed B cell lines. Eur. J. Immunol. 24, 2903-2909.

Wang JCL, Walle A, Novogrodsky A, Suthanthiran M, Silver RT, Bander NH, Rubin AL and Stenzel KH (1989).
A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2. J. Clinical Oncol. 7, 1885-1891.

Wang RL, Kong A-N T and Samelson LE (1992).
A tyrosine-phosphorylated 70-kDa protein binds a photoaffinity analogue of ATP and associates with both the ϵ chain and CD3 components of the activated T cell antigen receptor. J. Biol. Chem. 267, 11685-11688.

Wang RL, Malek SN, Desiderio S and Samelson LE (1993).
Tandem SH2 domains of ZAP-70 bind to T cell antigen receptor ζ and CD3 ϵ from activated Jurkat T cells. J. Biol. Chem. 268, 19797-19801.

Watanabe-Fukunaga R, Brannam CI, Copeland NG, Jenkins NA and Nagata S (1992).
Lymphoproliferation disorder in mice explained by defects in

Fas antigen that mediates apoptosis. Nature 356, 314-317.

Webb S and Sprent J (1987).
Down regulation of T cell responses by antibodies to the T cell receptor. J. Exp. Med. 165, 584-589.

Webb SR and Gascoigne NRJ (1994).
T-cell activation by superantigens. Current Opin. Immunol. 6, 467-475.

Wegener A-M K, Letourneur F, Hoeveler A, Brocker T, Luton F and Malissen B (1992).
The T cell Receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell 68, 83-95.

Weinberg K and Parkman R (1990).
Severe combined immunodeficiency due to a specific defect in the production of interleukin-2. New Eng. J. Med. 322, 1718-1723.

Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P and Garcia De Palazzo I (1993).
A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting *c-erbB-2* and CD16. Cancer Res. 53, 94-100.

Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL and Tso JY (1994).

The role of T cell activation in anti-CD3 X antitumor bispecific antibody therapy. J. Immunol. 152, 2385-2392.

Weintraub BC, Jackson MR and Hedrick SM (1994).
 $\gamma\delta$ T cells can recognize nonclassical MHC in the absence of conventional antigenic peptides. J. Immunol. 153, 3051-3056.

Weiss A, Wiskocil RL and Stobo JD (1984).
The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL2 production reflects events occurring at a pre-translational level. J. Immunol. 133, 123-128.

Weiss A and Imboden JB (1987).
Cell surface molecules and early events involved in human T lymphocyte activation. Adv. Immunol. 41, 1-38

Weiss A, Koretzky G, Schatzman RC and Kadlecsek T (1991).
Functional activation of the T-cell antigen receptor induces tyrosine phosphorylation of phospholipase C- γ 1. Proc. Natl. Acad. Sc. USA 88, 5484-5488.

Weiss A and Littman DR (1994).
Signal transduction by lymphocyte antigen receptors. Cell 76, 263-274.

Weiss A, Iwashima M, Irving B, van Oers NSC, Kadlecck TA, Straus D and Chan A (1994).

Molecular and genetic insights into T-cell antigen receptor signal transduction. Mechanisms of lymphocyte activation and immune regulation V. Gupta (Eds). Plenum Press, New York 53-62.

Weiss A, Kadlecck T, Iwashima M, Chan A and van Oers N (1995).

Molecular and genetic insights into T-cell antigen receptor signaling. Annals New York Acad. Sci. 766, 149-157.

Welte K, Andreeff M, Platzer E, Holloway K, Rubin BY, Moore MAS and Mertelsmann R (1984).

Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J. Exp. Med. 160, 1390-1403.

Wesselborg S, Janssen O and Kabelitz D (1993).

Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J. Immunol. 150, 4338-4345.

West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB and Oldham RK (1987).

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

New England J. Med. 316, 898-905.

Weynants P, Lethé B, Brasseur F, Marchand M and Boon T (1994).

Expression of MAGE genes by non-small-cell lung carcinomas.

Int. J. Cancer 56, 826-829.

Wiegmann K, Schüze S, Machleidt T, Witte D and Krönke M (1994).

Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling.

Cell 78, 1005-1015.

Whiteside TL and Heberman RB (1995).

The role of natural killer cells in immune surveillance of cancer.

Current Opin. Immunol. 7, 704-710.

Willems F, Andris F, Xu D, Abramowicz, Wissing M, Goldman M and Leo O (1995).

The induction of human T cell unresponsiveness by soluble anti-CD3 mAb requires T cell activation.

Int. Immunol. 7, 1593-1598.

Williams JM, Deloria D, Hansen JA, Dinarello CA, Loertscher R, Shapiro HM and Strom TB (1985).

The events of primary T cell activation can be staged by use of sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1.

J. Immunol. 135, 2249-2256.

Williams ME, Lichtman AH and Abbas AK (1990).

Anti-CD3 antibody induces unresponsiveness to IL-2 in Th1 clones but not in Th2 clones.

J. Immunol. 144, 1208-1214.

Williams ME, Shea CM, Lichtman AH and Abbas AK (1992).

Antigen receptor-mediated anergy in resting T lymphocytes and T cell clones. Correlation with lymphokine secretion patterns.

J. Immunol. 149, 1921-1926.

Williams N (1996).

An immune boost to the war on cancer.

Science 272, 28-30.

Witz IP and Ran M (1992).

FcR may function as a progression factor of nonlymphoid tumors.

Immunol. Res. 11, 283-295.

Wolf H, Müller Y, Salmen S, Wilmanns W and Jung G (1994).

Induction of anergy in resting human T lymphocytes by immobilized anti-CD3 antibodies.

Eur. J. Immunol. 24, 1410-1417.

Wong GH and Goeddel DV (1994).

Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways. J. Immunol. 152, 1751-1755.

Wong JT, Pinto CE, Gifford JD, Kurnick JT and Kradin RL (1989).

Characterization of the CD4+ and CD8+ tumor

infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
J. Immunol. 143, 3404-3411.

Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP and Bluestone JA (1991). Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.
Transplantation 52: 361-368.

Woodle ES, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre M-L and Bluestone JA (1992). Humanized OKT3 antidodies: successful transfer of immune modulating properties and idiotype expression.
J. Immunol. 148, 2756-2763.

Wotton D, Higgins JA, O'Hehir RE, Lamb JR and Lake RA (1995). Differential induction of the NF-AT complex during restimulation and the induction of T-cell anergy.
Hum. Immunol. 42, 95-102.

Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS and Bast RC (1992). Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor- α .

Am. J. Obstet. Gynecol. 166, 997-1007.

Yagita H, Nakata M, Azuma A, Nitta T, Takeshita T, Sugamura K and Okumura K (1989). Activation of peripheral blood T cells via the p75 interleukin 2 receptor.
J. Exp. Med. 170, 1445-1450.

Yagita H, Hanabuchi S, Asano Y, Tamura T, Nariuchi H and Okumura K (1995). Fas-mediated cytotoxicity - A new immunoregulatory and pathogenic function of Th1 CD4⁺ T cells.
Immunol. Rev. 146, 223-239.

Yamamoto N, Zou J-P, Li X-F, Takenaka H, Noda S, Fujii T, Ono S, Kobayashi Y, Mokaida N, Matsushima K, Fujiwara H and Hamaoka T (1995). Regulatory mechanisms for production of IFN- γ and TNF by antitumor T cells or macrophages in the tumor-bearing state.
J. Immunol. 154, 2281-2290.

Yamamoto T, Yoneda K, Osaki T, Yoshimura N and Akagi N (1995). Longer local of adoptively transferred T-Lak cells correlates with lesser adhesion molecule expression than NK-LAK cells.
Clin. Exp. Immunol. 100, 13-20.

Yang CY, Owen-Schaub L, Grimm EA and Roth JAI (1989). Induction of lymphokine-activated

killer cytotoxicity with interleukin-2 and tumor necrosis factor- α against primary lung cancer targets.
Cancer Immunol. Immunother. 29, 193-198.

Yang T-H, Aosai F, Norose K, Ueda M and Yano A (1995). Enhanced cytotoxicity of IFN- γ -producing CD4⁺ cytotoxic T lymphocytes specific for T. *goondii*-infected human melanoma cells.
J. Immunol. 154, 290-298.

Yannelli JR, Crumacker DB, Good RW, Friddell CD, Poston R, Horton S, Maleckar JR and Oldham RK (1990). Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy.
J. Immunol. Methods 1, 91-100.

Yokota S, Geppert TD and Lipsky PE (1988). Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor- α .
J. Immunol. 140, 531-536.

Yron I, Wood TA, Spiess PJ and Rosenberg SA (1980). In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.
J. Immunol. 125, 238-245.

Yun Y-S, Hagrove ME and Ting C-C (1989).

In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res. 49, 4770-4774.

Zelenin AV, Poletaev AI, Stepanova NG, Barsky VE, Kolesnikov VA, Nikitin SM, Zhuze AL and Gnutchev NV (1984). 7-Amino-actinomycin D as a specific fluorophore for DNA content analysis by laser flow cytometry. Cytometry 5, 348-354.

Ziegler SF, Morella KK, Anderson D, Kumaki N, Leonard W, Cosman D and Baumann H (1995). Reconstitution of a functional interleukin (IL)-7 receptor demonstrates that the IL-2 receptor γ chain is required for IL-7 signal transduction. Eur. J. Immunol. 25, 399-404.

Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA and Lotze MT (1995). Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155, 1393-1403.

Zola H, Neoh SH, Mantzioris BX, Webster J and Loughnan MS (1990). Detection by immunofluorescence of surface molecules present in low copy numbers. High sensitivity staining and calibration of flow cytometer. J. Immunol. Methods 135, 247-255.

Zhu Z and Carter P (1995). Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. J. Immunol. 155, 1903-1010.